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   Aminoacyl	   tRNA-­‐synthetases	   (AARS)	   are	   housekeeping	   enzymes	   that	   are	  
tasked	   with	   accurate	   synthesis	   of	   aminoacylated	   tRNA	   for	   protein	   synthesis	   and	  
other	   cellular	   functions.	   The	   specificity	   of	   amino	   acid	   attachment	   challenges	   the	  
AARSs	   that	   need	   to	   distinguish	   between	   structurally	   similar	   amino	   acids.	   In	   such	  
cases,	   AARSs	   have	   developed	   editing	   mechanisms	   to	   circumvent	   the	   issue	   of	  
misaminoacylation.	  	  
Leucyl-­‐tRNA	   synthetase	   (LeuRS),	   for	   instance	   selectively	   edits	   misactivated	  
and	   mischarged	   non-­‐leucine	   amino	   acids	   via	   pre-­‐transfer	   editing	   of	   misactivated	  
adenylates	  in	  the	  synthetic	  site	  or	  by	  hydrolyzing	  mischarged	  amino	  acids	  in	  the	  CP1	  
editing	  domain.	  The	  enzyme’s	  dependence	  between	  the	  two	  editing	  mechanisms	  can	  
shift	   based	   on	   the	   origin	   from	   which	   the	   AARS	   is	   derived,	   the	   amino	   acid	   that	   is	  
targeted	  for	  editing,	  or	  presence	  of	  a	  mutation	  in	  the	  enzyme.	  In	  the	  absence	  of	  the	  
CP1	  domain,	  E.	  coli	  LeuRS	   (LeuRS-­‐ΔCP1)	  maintains	   fidelity	   by	   clearing	  non-­‐leucine	  
aminoacyl-­‐adenylates	   in	   the	   enzyme’s	   synthetic	   site.	   The	   intact	   tRNA	   3’-­‐terminal	  
adenosine	  (A76)	  residue	  is	  a	  prerequisite	  for	  aminoacylation.	  	  
	   Leveraging	   A76	   essentiality	   tRNA	   analogues	   were	   designed	   to	   investigate	  
amino	   acid	   dependent	   specificity	   of	   editing	   by	   LeuRS.	   The	   tRNA	   analogues	   were	  
synthesized	   by	   addition	   of	   a	   modified	   adenosine	   triphosphate	   to	   an	   in	   vitro	  
transcribed	   E.	   coli	   tRNALeuUAA	   using	   the	   CCA-­‐adding	   enzyme	   from	   E.	   coli.	  
Incorporation	   of	   unchargeable	   tRNA	   analogues	   stimulated	   ATP	   hydrolysis	   by	  wild	  
	   	  iv	  
type	   LeuRS	   in	   the	   presence	   of	   norvaline.	   In	   contrast,	   pre-­‐transfer	   editing	   occurs	  
independent	  of	  the	  tRNA	  for	  LeuRS-­‐ΔCP1,	  which	  lacks	  the	  CP1	  domain.	  Therefore	  it	  is	  
hypothesized	  that	  the	  CP1	  domain	  of	  LeuRS	  plays	  a	  critical	  role	  for	  tRNA-­‐dependent	  
pre-­‐transfer	  editing.	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Chapter	  1:	  Introduction	  
	  
	  
1.1.	  Aminoacyl	  tRNA	  Synthetases	  and	  their	  Functions	  
Based	  on	  his	  analysis	  of	  ribosome	  structure,	  Francis	  Crick	  first	  hypothesized	  
that	  small	  nucleotide	  adaptors	  exist,	  which	  link	  amino	  acids	  to	  the	  genetic	  code.	  	  The	  
adaptor	  hypothesis	  originally	  appeared	  in	  1955	  as	  privately	  circulated	  notes	  of	  the	  
RNA	  tie	  club	  titled,	  “On	  Degenerate	  Template	  and	  the	  Adaptor	  Hypothesis”.	  The	  idea	  
was	   later	   formally	   published	   (Crick	   1958).	   Subsequently,	   transfer	   RNA	   (tRNA)	  
molecules	  were	  experimentally	  identified	  within	  the	  cell	  (Hoagland	  et	  al.	  1956).	  The	  
tRNA	   is	   an	   intracellular	   vehicle	   for	   the	   transport	   of	   amino	   acids	   to	   ribosome	   for	  
protein	  synthesis.	  Around	  the	  same	  time,	   tRNA	  ligases	  were	  also	  discovered	  (Berg	  
1956;	   Hoagland	   1955).	   This	   ancient	   superfamily	   of	   housekeeping	   enzymes	   also	  
referred	  to	  as	  aminoacyl-­‐tRNA	  synthetases	  (AARS)	  is	  tasked	  with	  the	  role	  of	  amino	  
acid	  attachment	  on	  to	  the	  tRNA	  (Ibba	  and	  Söll	  2000;	  Mascarenhas	  et	  al.	  2009;	  Pang	  
et	  al.	  2014).	  	  
Proper	   functioning	   of	   AARSs	   is	   crucial	   to	   accurate	   interpretation	   of	   the	  
genetic	  code	  during	  translation.	  The	  production	  of	  aminoacylated-­‐tRNA	  occurs	  in	  a	  
two-­‐step	   transesterification	   reaction	   at	   the	   AARS	   catalytic	   site	   (Fig	   1.1).	   The	   first	  
step	   activates	   amino	   acid	   in	   the	   presence	   of	   an	   adenosine	   triphosphate	   (ATP)	  
molecule.	   In	   the	   second	   transfer	   step,	   the	   activated	   intermediate,	   known	   as	   the	  
aminoacyl	   adenylate,	   attacks	   the	   tRNA	   3’-­‐terminal	   adenosine	   (A76)	   of	   the	   tRNA	  
	   	  2	  
(Loftfield	   1972).	   The	   resultant	   aminoacylated-­‐tRNA	   proceeds	   to	   the	   ribosome	   for	  

































































































Fig.	   1.1.	   Aminoacylation	   follows	   a	   two-­‐step	   mechanism.	   Step	   I	   involves	  
nucleophilic	  attack	  by	  the	  α-­‐carboxyl	  group	  of	   the	  amino	  acid	  on	  the	  α-­‐phosphate	  of	  
ATP	   generating	   an	   aminoacyl	   adenylate.	   	   This	   intermediate	   in	   Step	   II	   undergoes	   a	  
nucleophilic	  attack	  by	  either	  the	  2’	  or	  3’ hydroxyl	  group	  of	  the	  3’	  terminal	  adenosine,	  
A76	  of	  the	  tRNA. 
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Other	  than	  translation,	  AARSs	  also	  perform	  a	  number	  of	  alternate	  functions	  
critical	   to	   cell	   survival	   (Fig.	   1.3)	   that	  has	  been	   extensively	   reviewed	   (Brown	  et	   al.	  
2010;	  Guo	  and	  Schimmel	  2013;	  Lee	  et	  al.	  2004;	  Martinis	  et	  al.	  1999;	  Pang	  et	  al.	  2014;	  
Park	  et	  al.	  2005;	  Ryckelynck	  et	  al.	  2005;	  Yao	  et	  al.	  2014).	  While	  some	  of	  these	  non-­‐
translational	   functions	   have	   been	   attributed	   to	   the	   nucleic	   acid	   or	   amino	   acid	  
Fig.	  1.2.	  Role	  of	  AARSs	  in	  protein	  synthesis.	  The	  tRNA	  (grey)	  is	  aminoacylated	  at	  the	  
AARS	  in	  the	  presence	  of	  amino	  acid	  (AA)	  and	  ATP.	  The	  aminoacyl	  tRNA	  then	  proceeds	  
ribosome	  (blue)	  to	  deliver	  the	  AA	  required	  for	  peptide	  synthesis.	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binding	  ability	  of	  AARSs,	  other	  non-­‐canonical	  functions	  are	  on	  account	  of	  the	  highly	  
modular	  nature	  of	  AARSs.	  	  
	  
	  
The	   tRNA	   binding	   ability	   of	   AARS	   has	   been	   co-­‐opted	   for	   transcriptional	   or	  
translational	   regulation.	   For	   instance	   in	  E.	   coli,	   the	   promoter	   region	   of	   the	  mRNA	  
transcribed	   from	   the	   gene	   for	   ThrRS	   (ThrS)	  mimics	   tRNAThr	   (Romby	   et	   al.	   1992).	  
ThrRS	  was	  measured	  to	  have	  similar	  binding	  affinity	  for	  both	  tRNAThr	  and	  the	  ThrS	  
mRNA	   promoter.	   At	   low	   tRNA	   levels,	   the	   synthetase	   competes	   with	   the	   30S	  
ribosomal	   subunit	   for	   mRNA	   binding,	   thus	   blocking	   unproductive	   translation	   of	  
Fig.	  1.3.	  Functions	  of	  AARS	  in	  different	  cellular	  processes.	  AARSs	  are	  involved	  in	  a	  
number	   of	   alternate	   functions	   (blue)	   other	   than	   its	   canonical	   function	   of	  
aminoacylation	  and	  protein	  synthesis	  (red).	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ThrRS.	   (Moine	   et	   al.	   1990;	   Romby	   et	   al.	   1996).	   A	   similar	   mechanism	   of	   tRNA	  
mimicry	  in	  Salmonella	  typhimurium	  controls	  expression	  of	  proteins	  involved	  in	  the	  
histidine	  biosynthesis	  by	  HisRS	  (Ames	  et	  al.	  1983).	  	  
Specific	  AARSs	  have	  been	  shown	  to	  play	  important	  roles	  in	  cell	  signaling	  and	  
metabolism.	   For	   example,	   LeuRS	   operates	   as	  mediator	   in	   a	   signaling	   pathway	   for	  
cell	  growth	  via	  binding	  leucine,	  thus	  acting	  as	  a	  nutrient	  sensor	  (Bonfils	  et	  al.	  2012;	  
Han	   et	   al.	   2012).	  Mammalian	   target	   of	   rapamycin	   complex-­‐1	   (mTORC1),	   a	  master	  
growth	  regulator	  in	  the	  cell	  (Laplante	  and	  Sabatini	  2012),	  uses	  LeuRS	  as	  a	  sensor	  for	  
detecting	   leucine	   levels.	   This	   leucine-­‐sensing	   activity	   is	   based	   on	   the	   leucine	  
dependent	   binding	   of	   LeuRS	   and	  Rag	  GTPase,	   the	   amino	   acid	   sensor	   for	  mTORC1	  
(Han	   et	   al.	   2012).	   LeuRS	   has	   also	   been	   shown	   to	   interact	   with	   Vps34,	   a	   known	  
effector	  of	  mTORC1,	  in	  a	  leucine	  dependent	  manner	  (Yoon	  et	  al.	  2016).	  	  
Another	   alternate	   function	   that	   has	   been	   attributed	   with	   certain	   AARS	  
domains	   is	   cytokine	   like	   activity.	   For	   example	   the	   C-­‐terminal	   domain	   of	   TyrRS	  
shares	   a	   high	   degree	   of	   sequence	   similarity	  with	   endothelial	  monocyte	   activating	  
protein	  II	  (EMAP	  II)	  (Kleeman	  et	  al.	  1997).	  EMAP	  II	  is	  a	  pro-­‐inflammatory	  cytokine	  
with	   anti-­‐angiogenic	   properties	   that	   affects	   the	   biology	   of	   immunogenic	   tumors	  
(Kao	  et	  al.	  1992).	  This	  alternate	  function	  is	  independent	  of	  the	  aminoacylation	  role	  
of	  TyrRS	  as	  the	  C-­‐terminal	  domain	  is	  situated	  away	  from	  the	  catalytic	  core	  of	  TyrRS.	  	  
Other	   interesting	   novel	   functions	   of	   AARS	   have	   been	   identified	   via	   genetic	  
mutations	   implicating	   diseases.	   The	   link	   between	   AARS	   dysfunction	   and	   different	  
diseases	   has	   been	   discussed	   in	   several	   reviews	   (Antonellis	   and	   Green	   2008;	  
Ognjenović	  and	  Simonović	  2017;	  Park	  et	  al.	  2008;	  Sissler	  et	  al.	  2017).	  Mutations	  in	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AARSs	   have	   been	   associated	   with	   several	   diseases	   characterized	   by	   a	   range	   of	  
neuropathies.	  For	  example	  pathophysiological	  AARS	  missense	  mutations	  identified	  
in	   GlyRS	   were	   associated	   with	   Charcot-­‐Marie-­‐Tooth	   (CMT)	   disease,	   a	   disorders	  
affecting	  the	  peripheral	  nervous	  system	  (Antonellis	  et	  al.	  2003).	  Mutations	  causing	  
CMT	   were	   also	   identified	   in	   TyrRS	   (Jordanova	   et	   al.	   2006),	   HisRS	   (Vester	   et	   al.	  
2012),	  AlaRS	  (Latour	  et	  al.	  2010)	  and	  TrpRS	  (Tsai	  et	  al.	  2017).	  Surprisingly,	  some	  of	  
these	  mutant	  AARSs	  were	  functional	  with	  respect	  to	  aminoacylation	  activity	  (Nangle	  
et	  al.	  2007).	  This	  provides	  evidence	  that	  these	  mutations	  could	  impair	  an	  alternate	  
function	   other	   than	   the	   canonical	   aminoacylation.	   However,	   a	   single	   alternate	  
function	  that	  links	  all	  these	  AARSs	  and	  engenders	  the	  physiological	  response	  linked	  
to	  CMT	  remains	  elusive.	  	  
	  
1.2.	  Classification	  of	  Aminoacyl	  tRNA	  Synthetases	  
Most	  organisms	  contain	  a	  set	  of	  20	  AARSs,	  corresponding	  to	  each	  of	   the	  20	  
amino	   acids.	   These	   AARSs	   have	   diverged	   into	   two	   structurally	   disparate	   classes	  
(Table	   1.1)	   that	   recognize	   the	   similar	   substrates	   and	   perform	   the	   same	   function	  
(Cusack	   et	   al.	   1990;	   Eriani	   et	   al.	   1990).	   The	   class	   I	   AARSs	   have	   a	   Rossmann-­‐
dinucleotide	   fold	   (Rao	   and	   Rossmann	   1973;	   Risler	   et	   al.	   1981)	   while	   the	   class	   II	  
AARSs	   have	   an	   unusual	   antiparallel	   β-­‐fold	   (Cusack	   et	   al.	   1990)	   (Fig.	   1.4).	   Each	   of	  
these	  classes	  contains	  10	  AARSs	  and	  this	  distribution	  is	  conserved	  broadly	  across	  all	  
organisms	   (Cusack	   1997;	   Eriani	   et	   al.	   1990;	  Moras	   1992a).	   The	   only	   exception	   is	  
LysRS,	  which	  has	   also	   evolved	   as	   a	   class	   I	   enzyme	   in	   some	  organisms	   (Ibba	   et	   al.	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1997).	  These	  classes	  are	  further	  subdivided	  into	  three	  groups	  based	  on	  similarity	  in	  
structural	  motifs	  (Burbaum	  and	  Schimmel	  1991;	  Moras	  1992b)	  (Table	  1.2).	  	  
Table	  1.1:	  Distinction	  between	  Class	  I	  and	  II	  AARSs.	  
	  
	  
Features	   Class	  I	   Class	  II	  
Binding	  of	  ATP	   Extended	  conformation	   Bent	  Conformation	  
	  
Binding	  of	  tRNA	  
acceptor	  stem	  	  




hydroxyl	  group	  of	  A76	  
2’-­‐OH	   3’-­‐OH	  
	  
	  
Protein	  Structure	   Rossmann	  fold	   Antiparallel	  beta	  fold	  
	  
Oligomeric	  state	   Monomers	  occasionally	  
dimers	  
Always	  occur	  as	  dimers	  or	  
tetramers	  
	  
Signature	  sequence	   HIGH	  and	  KMSKS	   Motif	  I,	  II	  and	  III	  
	  
Fig.	   1.4.	   Structure	   comparison	   between	   Class	   I	   and	   Class	   II	   AARS.	   Structure	   of	  
Class	   I	  LeuRS	   (orange)	   in	  a	   complex	  with	  tRNALeu	   (dark	  blue)	   (Palencia,	  et	   al.,	  2012,	  
4AQ7)	   and	   that	   of	   Class	   II	   ThrRS	   (red)	   in	   complex	   with	   tRNAThr	   (light	   blue)	  
(Sankaranarayanan,	  et	  al.,	  1999,	  1QF6)	  can	  be	  observed.	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Table	  1.2:	  Classification	  of	  AARS	  based	  on	  amino	  acids	  charged.	  
1The	  designations	  M,	  D	  and	  T	  represent	  the	  monomeric,	  dimeric	  and	  tetrameric	  state	  
of	  the	  enzyme.	  
	  
It	   is	   not	   surprising	   that	   there	   are	   mechanistic	   differences	   between	   the	  
reactions	   performed	  by	   the	   two	   structurally	   different	   classes	   of	  AARSs.	   There	   are	  
two	  candidate	  hydroxyl	  positions	  present	  on	  the	  terminal	  adenosine-­‐76	  (A76)	  ribose	  
ring	   for	   transfer	   of	   the	   aminoacyl	   group.	   Early	   investigations	   revealed	   that	   some	  
tRNAs	   were	   aminoacylated	   at	   the	   2’	   OH	   group,	   while	   others	   at	   the	   3’	   OH	   group	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(Sprinzl	   and	  Cramer	  1975a).	   This	   preference	  was	   later	   attributed	   along	   the	  AARS	  
class	  split.	  The	  class	  I	  AARS	  interacts	  with	  the	  minor	  groove	  of	  3’-­‐terminus	  of	  tRNA	  
such	   that,	   aminoacyl	   transfer	   occurs	   at	   2’-­‐OH	   of	   the	   A76	  ribose	   ring	   (Rould	   et	   al.	  
1989).	   In	   contrast,	   class	   II	   AARS	   interact	   with	   tRNA	   3’-­‐terminus	   from	   the	   major	  
groove	  side,	  resulting	  in	  aminoacyl	  transfer	  at	  3’-­‐OH	  of	  A76	  ribose	  (Ruff	  et	  al.	  1991)	  
(Fig.	  1.5).	  
The	   LysRS	   is	   typically	   a	   class	   II	   synthetase.	   However,	   analysis	   of	   the	  
Methanococcus	  jannaschii	  genome	  only	  identified	  a	  condensed	  set	  of	  16	  synthetases	  
(Bult	   et	   al.	   1996;	  Tumbula	   et	   al.	   1999).	  One	  of	   the	   synthetases	   absent	  was	  LysRS.	  
Subsequently	   other	   organisms	   were	   observed	   that	   were	   missing	   this	   synthetase.	  
Further	  investigation	  revealed	  that	  LysRS	  was	  in	  fact	  present	  in	  these	  organism	  but	  
had	  a	  class	  I	  structure	  (Ibba	  et	  al.	  1997).	  Over	  the	  years	  it	  was	  established	  that	  the	  
occurrence	  of	  class	   I	  LysRS	  was	  a	  common	  feature	  among	  the	  archaea	  and	  certain	  
bacterial	  species	  (Woese	  et	  al.	  2000).	  
Other	  synthetases	  that	  were	  missing	  in	  M.	  jannaschii	  included,	  GlnRS,	  AsnRS	  
and	   CysRS.	   The	   absence	   of	   GlnRS	   and	   AsnRS	   can	   be	   easily	   explained	   based	   on	   a	  
previously	   known	   tRNA-­‐dependent	   transamidation	   pathway	   that	   converts	   Glu-­‐
tRNAGln	  to	  Gln-­‐tRNAGln(Schön	  et	  al.	  1988;	  Wilcox	  and	  Nirenberg	  1968).	  The	  first	  step	  
involves	   the	  mischarging	   of	   tRNAGln	  with	   glutamate	   by	   the	  GluRS	   to	   produce	  Glu-­‐
tRNAGln.	  In	  the	  subsequent	  step	  glutamate	  is	  converted	  to	  glutamine	  in	  the	  presence	  
of	  Glu-­‐Adt	  enzyme.	  A	  similar	  pathway	  was	  discovered	  for	  production	  of	  Asn-­‐tRNAAsn	  
in	  the	  absence	  of	  AsnRS	  (Curnow	  et	  al.	  1996).	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Fig.	  1.5.	  Functional	  comparison	  between	  Class	  I	  and	  Class	  II	  AARS.	  (A)	  The	  2’OH	  
from	  the	  ribose	  ring	  of	  A76	  at	  3’end	  of	  tRNALeu	  is	  oriented	  to	  undergo	  aminoacylation	  
by	  the	  adenylate	  analogue	  (silver)	  inside	  the	  active	  site	  of	  LeuRS	  (orange)	  (Palencia,	  et	  
al.,	   2012,	   4AQ7).	   (B)	   The	   3’OH	   from	   the	   ribose	   ring	   of	   A76	   at	   3’end	   of	   tRNAThr	   is	  
oriented	   to	   undergo	   aminoacylation	   by	   the	   adenylate	   analogue	   (silver)	   inside	   the	  
active	  site	  of	  LeuRS	  (red)	  (Sankaranarayanan,	  et	  al.,	  1999,	  1QF6).	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Different	   mechanisms	   have	   been	   suggested	   for	   the	   synthesis	   of	   the	   Cys-­‐
tRNACys.	   The	   initial	   hypothesis	   was	   that	   a	   ProRS	   would	   mischarge	   Cys-­‐tRNACys	  
(Stathopoulos	  et	  al.	  2000).	  It	  was	  later	  observed	  that	  there	  was	  an	  O-­‐phosphoseryl-­‐
tRNA	   synthetase	   (SepRS),	   which	   was	   responsible	   for	   attaching	   O-­‐phosphoserine	  
(Sep)	   on	   to	   tRNACys	   forming	   Sep-­‐tRNACys.	   In	   a	   second	   step	   a	   Sep-­‐tRNA:Cys-­‐tRNA	  
synthase	   (SepCysS)	   would	   convert	   Sep-­‐tRNACys	   to	   Cys-­‐tRNACys	   by	   a	   possible	  
sulfhydrylation	  reaction	  mechanism	  (Donoghue	  et	  al.	  2005;	  Sauerwald	  et	  al.	  2005).	  
	  
1.3.	  Editing	  Function	  of	  Aminoacyl	  tRNA	  Synthetases	  
In	   order	   to	  maintain	   fidelity,	   AARS	   needs	   to	   accurately	   recognize	   both	   the	  
cognate	  tRNA	  and	  amino	  acid.	  The	  rate	  of	  incorporation	  of	  an	  incorrect	  amino	  acid	  
into	  protein	  during	  translation	  was	  estimated	  at	  1	  in	  3000	  (Loftfield	  1963).	  Owing	  
to	   larger	   surface	  area	  available	   for	   interaction,	   tRNA	  recognition	  by	  AARS	   is	  more	  
efficient	   compared	   to	   selection	   of	   amino	   acids.	   In	   particular,	   amino	   acids	   with	  
structurally	   similar	   side	   chains,	   pose	   a	   threat	   to	  AARS	   fidelity	   (Mascarenhas	   et	   al.	  
2009).	  For	  example,	  the	  IleRS	  active	  site	  is	  challenged	  by	  valine,	  which	  differs	  from	  
isoleucine	  by	  absence	  of	  a	  single	  methyl	  group	  (Baldwin	  and	  Berg	  1966).	  Similarly,	  
AlaRS	  active	  site	  has	  difficulty	  fully	  discriminating	  between	  alanine	  from	  serine	  and	  
glycine	   (Beebe	   et	   al.	   2003;	   Tsui	   and	   Fersht	   1981),	  while	   isoleucine	   and	  norvaline	  
pose	  a	  threat	  to	  LeuRS	  fidelity	  (Englisch	  et	  al.	  1986;	  Karkhanis	  et	  al.	  2007a).	  	  
It	   was	   proposed	   that	   AARSs	   overcome	   the	   problem	   of	   amino	   acid	  
discrimination	  and	  maintain	  fidelity	  by	  utilizing	  a	  double	  sieve	  mechanism	  (Fersht	  
1977).	  It	  was	  hypothesized	  that	  the	  active	  site	  of	  AARS	  forms	  the	  first,	  coarse	  sieve	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that	   selects	   amino	   acids	   based	   on	   steric	   factors.	   Structurally	   similar	   amino	   acids	  
may	  be	   incorporated	   into	   the	   aminoacylation	   reaction	   at	   this	   stage.	  A	   second	   fine	  
sieve,	  an	  editing	  domain	  then	  hydrolyzes	  the	  misincorporated	  amino	  acids,	  thereby	  
maintaining	  fidelity	  (Fig.	  1.	  6).	  The	  AARSs	  that	  are	  known	  to	  possess	  editing	  activity	  
include	   the	   class	   I	   LeuRS	   (Englisch	   et	   al.	   1986),	   IleRS	   (Baldwin	   and	   Berg	   1966),	  
ValRS	  (Fersht	  and	  Kaethner	  1976)	  and	  MetRS	  (Fersht	  and	  Dingwall	  1979a);	  and	  the	  
class	   II	   AlaRS	   (Tsui	   and	   Fersht	   1981),	   ThrRS	   (Dock-­‐Bregeon	   et	   al.	   2000),	   PheRS	  





Fig.	  1.6.	  AARSs	  employ	  different	  mechanisms	  to	  edit	  mischarged	  tRNA.	  AARS	  (E)	  
catalyze	   the	   reaction	   between	   a	   molecule	   of	   amino	   acid	   (aa)	   and	   ATP	   to	   form	   the	  
aminoacyl-­‐adenylate	   (aa-­‐AMP)	   releasing	   a	   pyrophosphate	   (PPi)	   molecule.	   An	  
incorrectly	  activated	  adenylate	  can	  be	  hydrolyzed	  through	  pre-­‐transfer	  editing	  either	  
in	   a	   tRNA	   dependent	   or	   independent	   fashion.	   Mischarged	   aminoacyl-­‐tRNA	   can	   be	  
hydrolyzed	  through	  the	  post-­‐transfer	  editing	  mechanism.	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Editing	   could	   potentially	   occur	   at	   the	   end	   of	   each	   step	   of	   the	   two-­‐step	  
aminoacylation	   reaction.	   Pre-­‐transfer	   editing	   occurs	   after	   the	   first	   step	   of	  
aminoacylation,	  where	  the	  misactivated	  adenylate	  is	  hydrolyzed	  at	  the	  AARS	  active	  
site	   (Fersht	   and	   Dingwall	   1979b).	   This	   process	   can	   occur	   with	   or	   without	   the	  
assistance	   of	   tRNA	  molecule.	   Editing	   activity	   that	   occurs	   after	   the	   second	   step	   of	  
aminoacylation	   is	   known	   as	   post-­‐transfer	   editing	   (Eldred	   and	   Schimmel	   1972).	  
Fig.	   1.7.	   Post-­‐transfer	   editing	   of	   LeuRS	   via	   the	   double	   sieve	  model.	  The	  double	  
sieve	  model	  (Fersht,	  et	  al.,	  1977)	  shows	  that	  the	  catalytic	  core	  of	  AARS	  (yellow)	  acts	  as	  
a	   coarse	   sieve,	   eliminating	   sterically	   incompatible	   amino	   acids	   (represented	   as	  
magenta	  triangles,	  blue	  diamonds	  and	  olive	  ellipses).	  Structurally	  similar	  amino	  acids	  
(red	   squares)	   that	   are	   activated	   undergo	   hydrolytic	   editing	   by	   the	   fine	   sieve	   of	   the	  
editing	   domain	   (blue).	   While	   the	   tRNA	   charged	   with	   cognate	   amino	   acid	   (green	  
squares)	  is	  free	  to	  leave	  the	  active	  site	  (Mursinna	  et	  al.,	  2001).	  The	  crystal	  structure	  of	  
E.	  coli	  LeuRS	  (Palencia,	  et	  al.,	  2012,	  4AQ7)	  is	  represented	  on	  the	  right.	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During	  this	  process	  a	  misaminoacylated	  tRNA	  gets	  hydrolyzed	  (Fig.	  1.7).	  AARSs	  can	  
have	  preference	  for	  pre-­‐	  versus	  post-­‐transfer	  editing	  depending	  on	  the	  amino	  acid	  
being	  edited	  or	  the	  origin	  of	  the	  synthetase	  (Martinis	  and	  Boniecki	  2010;	  Sarkar	  and	  
Martinis	  2011).	  	  
The	   class	   Ia	   synthetases,	   IleRS,	   ValRS	   and	   LeuRS,	   hydrolytically	   edit	  
mischarged	   amino	   acids	   via	   a	   homologous,	   appended	   connective	   polypeptide	   1	  
domain	   (CP1)	   (Lin	   et	   al.	   1996;	   Mursinna	   et	   al.	   2004).	   While	   ValRS	   prefers	   post-­‐
transfer	  editing,	   IleRS	  mostly	  edits	  via	   the	  pre-­‐transfer	  editing	  mechanism	  (Fersht	  
1977).	  In	  the	  case	  of	  LeuRS,	  the	  synthetase	  from	  E.	  coli	  has	  a	  dominant	  post-­‐transfer	  
editing.	   However,	   the	   yeast	   LeuRS	   utilizes	   the	   pre-­‐transfer	   editing	   mechanism	  
(Boniecki	  et	  al.	  2008;	  Englisch	  et	  al.	  1986).	  	  
Unlike	   other	   editing	   members	   of	   class	   Ia	   synthetases,	   MetRS	   has	   a	   much	  
smaller	  CP1	  domain	  (Mechulam	  et	  al.	  1999).	  However,	  MetRS	  is	  confounded	  by	  the	  
sterically	  similar	  non-­‐standard	  homocysteine,	  which	  undergoes	  adenylate	  formation	  
at	   its	   active	   site	   (Fersht	   and	   Dingwall	   1979a).	   In	   the	   absence	   of	   CP1	   editing,	   the	  
activated	   homocysteine	   is	   converted	   to	   homocysteinyl	   thiolactone	   for	   elimination	  
(Jakubowski	   1990;	   Jakubowski	   and	   Fersht	   1981).	   The	  MetRS	   active	   site	   performs	  
editing	   based	   on	   the	   difference	   in	   orientation	   between	   the	   methioninyl	   and	  
homocysteinyl	   adenylate.	   While	   methioninyl	   adenylate	   has	   a	   linear	   orientation	  
(Serre	  et	  al.	  2001),	  homocysteinyl	  adenylate	  is	  bent	  allowing	  thiolactone	  formation	  
via	   a	   cyclization	  mechanism	   (Jakubowski	   2001).	   The	   class	   II	   LysRS	   also	   follows	   a	  
cyclization	   mechanism	   (Jakubowski	   1997)	   for	   editing	   mischarged	   homocysteine,	  
homoserine	  and	  ornithine	  (Jakubowski	  1999).	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Editing	   domains	   for	   other	   class	   II	   synthetase,	   AlaRS,	   ThrRS,	   PheRS	   and	  
ProRS,	  differ	  significantly.	  Though	  there	  exists	  some	  similarity	  between	  the	  class	  IIa,	  
AlaRS	  and	  ThrRS,	  they	  are	  present	  in	  different	  regions	  of	  the	  synthetase.	  While	  the	  
ThrRS	  editing	  domain	  is	  located	  near	  the	  N-­‐terminus	  (Beebe	  et	  al.	  2004),	  the	  AlaRS	  
editing	  domain	  is	  located	  at	  the	  C-­‐terminus	  (Beebe	  et	  al.	  2003).	  The	  ProRS,	  insertion	  
domain	  (INS)	  responsible	   for	  editing,	  does	  not	  share	  any	  similarity	  with	   the	  other	  
class	   IIa	   editing	   domains	   (Wong	   et	   al.	   2002).	   The	   class	   IIc	   PheRS	   is	   significantly	  
different	  from	  the	  class	  IIa	  domains	  (Roy	  et	  al.	  2004).	  
Examples	  discussed	  so	  far	  pertain	  to	  editing	  activity	  carried	  out	  either	  by	  the	  
synthetase	   or	   one	  of	   its	   appended	  domains.	   This	   is	   also	   referred	   to	   as	   cis-­‐editing.	  
However,	   freestanding	   editing	   domains	   (Fig.	   1.8)	   have	   been	   identified	   that	   are	  
capable	   of	   trans-­‐editing.	   For	   instance,	   AlaX	   is	   an	   independently	   occurring	   protein	  
that	   resembles	   the	   editing	   domain	   of	   AlaRS	   and	   edits	   the	  mischarged	  Gly-­‐tRNAAla	  
and	  Ser-­‐tRNAAla	  (Ahel	  et	  al.	  2003).	  
Trans-­‐editing	   is	   also	   observed	   in	   the	   case	   of	   proline	   where	   two	   distinct	  
editing	  domains	  have	  been	   identified.	  The	  ProX	  domain	  shares	   similarity	  with	   the	  
ProRS	   editing	   domain	   and	   hydrolyzes	   mischarged	   Ala-­‐tRNAPro	   (Ahel	   et	   al.	   2003).	  
Ybak	  on	  the	  other	  hand,	  edits	  the	  incorrectly	  charged	  Cys-­‐tRNAPro	  (An	  and	  Musier-­‐
Forsyth	   2005).	   While	   ProX	   acts	   independently	   of	   ProRS,	   Ybak	   in	   the	   absence	   of	  
ProRS	  lacks	  tRNA	  specificity	  (Das	  et	  al.	  2014).	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Fig.	  1.8.	   Structure	  of	   common	   free	  standing	   editing	  domains.	  Structures	  of	  AlaX	  
(A)	  (Sokabe,	  et	  al.,	  2005,	  1WNU)	  from	  P.	  horikoshi,	  ProX	  (B)	  (Murayama,	  et	  al.,	  2007,	  
2Z0K,	  green)	  from	  T.	  thermophilus	  and	  ybaK	  (C)	  (Zhang,	  et	  al.,	  2000,	  1DBU,	  blue)	  from	  
H.	  influenezae	  are	  represented	  in	  gold,	  green	  and	  blue,	  respectively.	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1.4.	  Structure	  and	  Classification	  of	  tRNA	  
	   In	   1965,	   Robert	  Holley	   suggested	   the	   cloverleaf	   secondary	   structure	   based	  
on	   the	   primary	   sequence	   of	   yeast	   tRNAAla	  that	   was	   available	   (Holley	   et	   al.	   1965).	  
Essential	  features	  observed	  in	  tRNA	  secondary	  structure	  includes	  the	  acceptor	  stem,	  
dihydouridine	  loop	  (D-­‐loop),	  anticodon	  stem-­‐loop,	  variable	  arm	  and	  pseudouridine	  
loop	   (TΨC	   loop).	   Alexander	   Rich	   obtained	   the	   first	   tRNA	   structure	   for	   yeast	  
tRNAPheGAA	   in	   1973.	   The	   crystallographic	   studies	   showed	   that	   the	   tRNA	   cloverleaf	  
folded	   into	   an	   elegant	   L-­‐shaped	   tertiary	   structure	   (Kim	  et	   al.	   1973).	   The	   acceptor	  
stem	  stacks	  over	  the	  D-­‐stem	  to	  give	  one	  perpendicular	  arm	  of	  the	  L-­‐shape,	  while	  the	  
other	  arm	  is	  formed	  by	  the	  interaction	  between	  the	  anti-­‐codon	  stem	  and	  the	  T-­‐stem	  
(Fig.	  1.9).	  
	  
Fig.	   1.9.	   Structural	   elements	   of	   tRNA.	   	   A)	   Represents	   the	   cloverleaf	   secondary	  
structure	   of	   tRNA.	   B)	   Represents	   the	   tertiary	   structure	   for	   tRNAPhe	   (4TNA).	  
Acceptor	  stem,	  D-­‐loop,	  variable	  arm	  and	  TψC	  loop	  are	  shown	  in	  red,	  green,	  purple,	  
yellow	  and	  blue	  respectively.	  The	  discriminator	  base	  (D73)	  and	  anticodon	  bases	  are	  
colored	  in	  black.	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Analysis	   of	   tRNA	   sequences	   from	   several	   different	   organisms	   showed	   that	  
the	   length	   of	   cytoplasmic	   tRNAs	   typically	   varied	   between	   73-­‐93	   nucleotides	  
(Brennan	   and	   Sundaralingam	   1976;	   Jühling	   et	   al.	   2009).	   The	   difference	   in	   length	  
between	  different	  tRNAs	  is	  due	  to	  the	  variability	  in	  number	  of	  nucleotides	  present	  in	  
the	  D-­‐loop	  and	  the	  variable	  arm	  (Fig	  1.10).	  In	  fact,	  the	  length	  of	  the	  variable	  arm	  is	  
used	  as	  basis	  for	  classification	  of	  tRNA.	  The	  type	  I	  tRNAs	  have	  a	  4-­‐5	  nucleotides	  in	  
the	  variable	  arm.	  On	  the	  other	  hand,	  type	  II	  tRNAs	  have	  an	  extra	  long	  variable	  arm,	  
which	   can	   have	   up	   to	   23	   nucleotides.	   All	   tRNAs	   are	   type	   I,	   with	   the	   exception	   of	  
tRNASer	  and	  tRNASec	  that	  are	  type	  II.	  The	  tRNATyr	  is	  a	  type	  I	  tRNA	  in	  eukaryotes	  and	  a	  
type	   II	   tRNA	   in	  prokaryotes	   (Sprinzl	   et	   al.	   1989).	  The	   tRNALeu	  were	   thought	   to	  be	  
type	   II	   across	   all	   organisms.	   However,	   bioinformatics	   analysis	   of	   bacterial	   tRNA	  
revealed	   atypical	   type	   I	   tRNALeu	   sequences.	   In	   direct	   contradiction	   to	   type	   I	   or	   II	  
conservation	  of	  tRNA,	  bacterial	  species	  have	  now	  been	  identified	  that	  comprise	  both	  
type	  I	  and	  type	  II	  tRNALeu	  molecules	  (unpublished	  results).	  
The	   translation	   machinery	   is	   built	   around	   the	   tRNA	   architecture.	  
Conservation	  of	  the	  distance	  between	  amino	  acid	  at	  one	  end	  of	  the	  L-­‐shaped	  tRNA	  
and	  anticodon	  at	  the	  other	  is	  therefore	  critical.	  Thus	  one	  would	  believe	  that	  all	  tRNA	  
molecules	  must	  have	   the	  cloverleaf	   structure.	  However,	  mitochondrial	   (mt)	   tRNAs	  
are	  unusual.	  For	  example,	  the	  human	  mt-­‐tRNASer	  shows	  divergence	  from	  cloverleaf	  
structure	  (Anderson	  et	  al.	  1981).	  It	  is	  missing	  the	  D-­‐loop,	  essential	  for	  maintaining	  
the	  integrity	  of	  the	  L-­‐shaped	  tertiary	  structure.	  Interestingly,	  the	  human	  mt-­‐tRNASer	  
preserves	  functionality	  by	  adopting	  a	  boomerang-­‐like	  structure	  (Hanada	  et	  al.	  2001;	  
Mustoe	  et	  al.	  2015).	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An	  amino	  acid	   can	  be	   represented	  by	  more	   that	  one	   codon.	  An	   isoacceptor	  
tRNA	   recognizes	   these	   individual	   codons	  while	   being	   specific	   for	   the	   same	   amino	  
acid.	  For	  example	  leucine	  is	  coded	  by	  UUA,	  UUG,	  CUU,	  CUC,	  CUA	  and	  CUG.	  Thus,	  an	  
Fig.	  1.10.	  Classification	  of	  tRNA	  based	  on	  size	  of	  the	  variable	  arm.	  A)	  Type	  I	  
tRNAs	  have	  a	   short	  variable	  arm.	   The	   clover-­‐leaf	   structure	   for	   type	   I	   tRNA	  and	  
the	   crystal	   structure	   of	   tRNAPhe	  (cyan,	   4TNA)	   are	   shown	   on	   the	   left	   and	   right	  
respectively.	   B)	   Type	   II	   tRNAs	  have	  an	  extra	   long	   variable	   arm.	  The	   clover-­‐leaf	  
structure	  for	  type	  II	  tRNA	  and	  	  the	  crystal	  structure	  of	  tRNALeu	  (gold,	  	  4AQ7)	  are	  
shown	  on	  the	  left	  and	  right	  respectively.	  
	  
	   	  20	  
organism	   could	   possess	   a	   set	   of	   6	   isoacceptors	   for	   tRNALeu,	   one	   for	   each	   codon.	  
Isodecoder	   tRNAs	   recognize	   the	   same	   anticodon	   and	   amino	   acid	   but	   differ	   have	  
sequence	  differences	  in	  the	  tRNA	  body	  (Goodenbour	  and	  Pan	  2006).	  In	  E.	  coli	  K-­‐12	  
MG	  1655,	  there	  are	  5	  tRNALeu	  isoacceptors	  and	  4	  isodecoders	  for	  tRNALeuCAG	  (Chan	  
and	  Lowe	  2016).	  
	   	  
1.5.	  Recognition	  of	  tRNA	  by	  AARSs	  
Every	  amino	  acid	  has	  a	  set	  of	  cognate	  isoacceptors	  and	  isodecoders	  that	  the	  
AARS	  must	   recognize.	   Though	   tRNA	  molecules	   share	   significant	   similarities,	   there	  
exist	  differences	  between	   individual	   tRNAs.	  These	  constitute	   the	   identity	  elements	  
that	   facilitate	   selection	   of	   cognate	   tRNA	   by	   AARSs.	   In	   addition	   to	   positive	  
determinants,	   there	   are	   also	   anti-­‐determinants	   that	   inhibit	   non-­‐cognate	  
interactions.	  The	  acceptor	  stem	  receives	  the	  amino	  acid	  during	  charging,	  while	  the	  
anticodon	  base	  pairs	  with	   the	  mRNA	  triplet	  codon.	  Thus,	  by	  virtue	  of	   their	   role	   in	  
translation,	  they	  are	  also	  a	  good	  choice	  for	  commonly	  used	  identity	  elements.	  	  Other	  
identity	   elements	   and	   anti-­‐determinants	   include	   discriminator	   base	   and	   variable	  
arm.	  
1.5.1	  Discriminator	  Base	  
	   The	  nucleotide	  appearing	  at	  position	  73	  of	  3’-­‐terminus	  of	  tRNA	  is	  known	  as	  
the	  discriminator	  base	  (D73)	  (Crothers	  et	  al.	  1972).	  It	  is	  followed	  by	  the	  universally	  
conserved	   CCA	  nucleotides	   that	   are	   essential	   for	   aminoacylation.	   Though	   variable	  
between	   different	   tRNAs,	   D73	   is	   surprisingly	   conserved	   among	   tRNA	   isoacceptors,	  
making	  it	  an	  excellent	  candidate	  for	  an	  identity	  element.	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Analysis	  of	  tRNA	  identity	  elements	  in	  E.	  coli	  revealed	  that	  18	  of	  the	  20	  AARSs	  
use	  D73	   for	   recognition	   (Giegé	   et	   al.	   1998).	   GluRS	   (Sylvers	   et	   al.	   1993)	   and	  ThrRS	  
(Hasegawa	  et	  al.	  1992)	  being	  the	  only	  AARSs	  from	  E.	  coli	  that	  do	  not	  utilize	  D73	  as	  an	  
identity	  element.	  Replacing	  A73	  of	  tRNALeu	  from	  E.	  coli,	  decreases	  its	  aminoacylation	  
by	   the	   LeuRS	   following	   the	   order	   A>C>U>G	   (Asahara	   et	   al.	   1993).	   In	   another	  
example,	   replacing	   tRNALeu	   A73	  with	   G,	   that	   is	   found	   at	   the	   discriminator	   site	   of	  
tRNASer	  enables	   its	  recognition	  by	  SerRS,	  providing	  further	  evidence	  for	  role	  of	  D73	  
in	  tRNA	  identity	  (Normanly	  et	  al.	  1992).	  	  
1.5.2	  Amino	  Acid	  Acceptor	  Stem	  
	   The	  acceptor	  stem	  is	  composed	  of	  a	  7	  base	  pair	  double-­‐stranded	  stem	  and	  a	  4	  
nucleotide,	   D73CCA76,	   single	   strand	   that	   is	   charged	   with	   an	   amino	   acid.	   During	  
aminoacylation,	   there	   is	   direct	   contact	   between	   the	   synthetase	   active	   site	   and	   the	  
acceptor	  stem,	  making	  it	  ideal	  for	  positioning	  identity	  elements.	  The	  tRNAAla	  has	  an	  
idiosyncratic	   G3:U70	   wobble	   pair	   in	   the	   acceptor	   stem	   region	   (Hou	   and	   Schimmel	  
1988;	  McClain	   and	   Foss	   1988).	   The	   AlaRS	   active	   site	   is	   designed	   to	   leverage	   this	  
unique	   tRNA	   feature	   for	   recognition	   (Chang	   et	   al.	   1999;	   Naganuma	   et	   al.	   2014).	  
Interestingly,	  this	  same	  feature	  acts	  as	  an	  anti-­‐determinant	  and	  causes	  a	  mismatch	  
between	  tRNAAla	  and	  ThrRS	  (Nameki	  1995).	  	  
The	   smallest	  unit	   aminoacylated	  by	  HisRS	   is	   a	  microhelix	   corresponding	   to	  
the	   tRNAHis	   acceptor	   stem	   (Francklyn	   and	   Schimmel	   1990).	   The	   unusual	   acceptor	  
stem	   of	   tRNAHis	   contains	   an	   additional	   5’	   terminal	   guanosine	   nucleotide	   (G-­‐1)	  
(Jühling	   et	   al.	   2009).	   This	   peculiarity	   acts	   as	   a	   strong	   determinant	   that	   enables	  
cognate	  recognition.	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1.5.3	  Anticodon-­‐Binding	  Region	  
	   The	   tRNA,	   through	   specific	   interaction	   of	   its	   triplet	   anticodon	   with	   the	  
mRNA,	   decrypts	   the	   genetic	   code.	   Dependence	   of	   amino	   acid	   selectivity	   on	   the	  
anticodon	   makes	   this	   tRNA	   region	   a	   prospective	   site	   for	   identity	   elements.	   Most	  
tRNAs,	  with	  the	  exception	  of	  tRNALeu,	  tRNAAla	  and	  tRNASer	  use	  the	  anticodon-­‐binding	  
region	  as	  an	  identity	  element	  (Giegé	  et	  al.	  1998).	  A	  seminal	  example	  for	  use	  of	  the	  
anticodon	  as	  an	   identity	  element	   is	   lysidine	  modification	  of	  C34	   in	  E.	  coli	   tRNAIleCAU	  
(Muramatsu	   et	   al.	   1988).	   This	  minor	   tRNA	   is	   significantly	   aminoacylated	   by	   IleRS	  
only	   in	   the	  presence	  of	   lysidine	  modification,	  which	  also	  enables	   its	  recognition	  of	  
AUA	   codon	   specific	   for	   isoleucine.	   The	   absence	   of	   modification	   allows	   for	  
recognition	  by	  AUG	  codon	  for	  methionine.	  Interestingly,	  the	  unmodified	  tRNAIleCAT	  is	  
aminoacylated	  by	  MetRS,	  thus	  acting	  as	  a	  specificity	  switch	  on	  the	  tRNA.	  	  
1.5.4	  Variable	  Arm	  
	   The	   type	   II	   tRNAs	   for	   Ser,	   Leu	   and	   Tyr	   have	   the	   extra-­‐long	   variable	   arm,	  
which	  can	  act	  as	  an	  identity	  element	  by	  virtue	  of	  additional	  unique	  interactions	  with	  
the	   AARSs.	   The	  most	   important	   example	   is	   the	   tRNASer	   variable	   arm	   acting	   as	   an	  
identity	   element,	   replacing	   it	   with	   a	   type	   I	   variable	   arm	   diminishes	   the	  
aminoacylation	  by	  SerRS	  (Sampson	  and	  Saks	  1993).	  The	  significance	  of	  variable	  arm	  
as	  an	  identity	  element	  is	  reflected	  in	  the	  crystal	  structure	  of	  SerRS	  complexed	  with	  
tRNASer.	  The	  synthetase	  makes	  contact	  with	  the	  variable	  arm	  upto	  its	  6th	  base	  pair,	  
thereby	  setting	  a	  minimum	  length	  requirement	  (Biou	  et	  al.	  1994).	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1.6.	  Identity	  Elements	  For	  tRNALeu	  
Other	   than	   the	   discriminator	   base	   tRNALeu	   also	   uses	   tertiary	   interactions	  
between	   the	   D-­‐loop	   and	   TC-­‐loop	   as	   identity	   elements	   (Table	   1.3).	   The	   smallest	  
tRNALeu	   that	   can	  be	  aminoacylated	  by	  LeuRS	  consists	  of	   the	  acceptor	   stem,	  D-­‐arm	  
and	  the	  TC-­‐arm(Larkin	  et	  al.	  2002).	  Therefore,	  tRNALeu	  from	  most	  species	  does	  not	  
use	  the	  variable	  arm	  or	  the	  anticodon-­‐binding	  arm	  for	  recognition.	  
Table	  1.3:	  Identity	  elements	  for	  tRNALeu.	  
Origin	  of	  tRNALeu	   Identity	  elements	   Reference	  
E.	  coli	   Discriminator	  base	  (A73)	  
	  
D-­‐loop	  residues	  G18,	  G19	  
	  
A14:U48	  base	  pair	  
(Asahara	  et	  al.	  1993)	  
(Normanly	  et	  al.	  
1992)	  
(Asahara	  et	  al.	  1998)	  
(Larkin	  et	  al.	  2002)	  
	  
	  
Human	   Discriminator	  base	  (A73)	  
	  
Acceptor	  stem	  base	  pairs	  3:70,	  4:69,	  
5:68	  
	  
C20a	  in	  DHU	  loop	  	  
	  
Extra	  long	  variable	  arm	  
(Breitschopf	  et	  al.	  
1995)	  
(Metzger	  et	  al.	  1997)	  
Yeast	   Discriminator	  base	  (A73)	  
	  
Anticodon	  stem	  loop	  A35	  and	  G37	  
	  
(Soma	  et	  al.	  1996)	  
	  
Unlike	  other	  Class	  Ia	  synthetases,	  LeuRS	  C-­‐terminal	  domain	  does	  not	  interact	  
with	  the	  tRNA	  anticodon-­‐binding	  stem.	  However,	  the	  LeuRS	  C-­‐terminal	  domain	  has	  
an	   extension	   that	   contacts	   the	   tRNA	   junction	   formed	   by	   the	   D-­‐loop	   and	   T-­‐loop,	  
facilitating	   identification	   (Palencia	   et	   al.	   2012;	   Tukalo	   et	   al.	   2005).	   Lack	   of	  
aminoacylation	   activity	   in	   carefully	   designed	   G18A:U55C	   and	   G19A:C56U	   mutants,	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which	  preserve	  tRNA	  structure,	  further	  provides	  evidence	  for	  the	  role	  of	  these	  base	  
pairs	  as	  identity	  elements	  in	  E.	  coli	  tRNALeu(Larkin	  et	  al.	  2002).	  
In	  contrast	  to	  type	  II	  tRNASer,	  tRNALeu	  with	  the	  exception	  of	  that	  from	  yeast,	  
does	   not	   use	   its	   variable	   arm	   for	   recognition.	   The	   tRNALeu	   from	   Saccharomyces	  
cereviciae	   is	   different	   from	   its	   counterpart	   from	  other	  organisms.	  The	  A35	   and	  G37	  
nucleotides	  of	  the	  anticodon	  loop	  form	  important	  identity	  elements	  for	  this	  tRNALeu	  
(Soma	  et	  al.	  1996).	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Radiolabeled	  nucleotide	  [α-­‐32P]-­‐ATP	  (3000	  Ci/mmol)	  as	  well	  as	  radiolabelled	  
amino	  acids	  [3H]-­‐isoleucine	  (97	  Ci/mmol)	  and	  [14C]-­‐leucine	  (150.1	  Ci/mmol)	  were	  
purchased	   from	   PerkinElmer	   (Boston,	   MA).	   The	   Vent	   DNA	   polymerase	   and	  
restriction	  digestion	  enzymes	  namely,	  EcoR	  I,	  BstN	  I	  and	  Bbs	  I	  were	  obtained	  from	  
New	  England	  Biolabs	   Inc.	   (Beverly,	  MA).	  The	  HisPur™	  Ni-­‐NTA	  Resin	  was	  obtained	  
from	   Thermo	   SCIENTIFIC	   (Rockford,	   IL).	   The	   BL21	   (DE3)pLysS	   cells	   for	   protein	  
expression	   were	   from	   Novagen	   (Madison,	   WI).	   The	   polyethyleneimine	   cellulose	  
plates	  with	   fluorescent	  marker	   (PEI-­‐F)	   used	   for	   thin	   layer	   chromatography	   (TLC)	  
were	   acquired	   from	   J.T.	   Baker	   (Phillipsburg,	   NJ).	   The	   DNA	   oligonucleotides	   were	  
synthesized	   by	   Integrated	   DNA	   technologies	   (Coralville,	   IA).	   The	   ATP	   analogues,	  
2’dATP	  and	  3’NH2-­‐ATP	  were	  purchased	  from	  Sigma	  (St.	  Louis,	  MO)	  and	  BioLog	  Life	  
Sciences	   Institute	   (Bremen,	   Germany)	   respectively.	   The	   plasmid	   encoding	   E.	   coli	  
was	  obtained	  from	  Dr.	  X.	  Yang	  	  at	  Scripps.	  
	  
2.2.	  Expression	  and	  Purification	  of	  Proteins	  
Plasmids	   p15ec3(Mursinna	   et	   al.	   2001)	   encoding	   wild	   type	   E.	   coli	   LeuRS,	  
p15MTVecLeuRSdCP1	   encoding	   E.	   coli	  LeuRSΔCP1(Boniecki	   et	   al.	   2008),	   pT7-­‐911	  
encoding	   T7	   RNA	   polymerase(Ilia	   E.	   Ichetovkin	   1997;	   Parichehre	   Davanloo	   1984)	  
and	  pET-­‐22-­‐CCA	  encoding	  CCA-­‐adding	  enzyme	  from	  E.	  coli	  (obtained	  from	  Yang	  lab	  
	   	  26	  
Scripps)	   were	   used	   to	   transform	   E.	   coli	   BL21	   (DE3)	   expression	   cells	   (Novagen,	  
Madison,	  WI).	  	  
Transformants	  were	   selected	  on	  media	   containing	  100	  μg/mL	  ampicillin.	  A	  
single	   transformant	   colony	   was	   incubated	   overnight	   at	   37	   °C	   in	   5	   mL	   of	   Lauria	  
Bertani	   broth	   containing	   100	   μg/mL	   ampicillin.	   The	   overnight	   5	   mL	   culture	   was	  
then	  used	  to	  inoculate	  1	  L	  of	  autoclaved	  LB.	  Cells	  were	  grown	  at	  37	  °C	  with	  shaking	  
to	   an	   OD600	   of	   ~	   0.6.	   These	   cells	   were	   then	   induced	   with	   isopropyl-­‐β-­‐D-­‐
thiogalactopyranoside	   (IPTG)	   added	   to	   a	   final	   concentration	   of	   1	  mM	   followed	  by	  
incubation	   for	  3	  hours	  at	  37	   °C.	  The	  cells	  were	  harvested	  by	  centrifugation	   for	  15	  
min	  at	  6,000	  rpm	  and	  4	  °C	  using	  a	  Beckman	  Coulter	  Avanti	  JE	  centrifuge	  (Beckman	  
Coulter	  Inc.,	  Fullerton,	  CA).	  	  
The	  cell	  pellet	  was	  suspended	  in	  lysis	  buffer	  (50	  mM	  KPi	  buffer	  pH	  7.5,	  5	  mM	  
MgCl2,	  300	  mM	  KCl,	  5%	  glycerol,	  5	  mM	  β-­‐mercaptoethanol,	  Roche	  cOmplete	  Tablets	  
EDTA-­‐free,	  EASY-­‐pack)	  and	  sonicated	  using	  Branson	  Sonifier	  450	  (VWR	  Scientific)	  
at	  18W	  for	  2	  min	  on	  ice	  using	  a	  2	  sec	  pulse.	  The	  sonication	  cycle	  was	  repeated	  once	  
more	  for	  2	  min.	  Cell	  lysate	  was	  then	  centrifuged	  for	  30	  min	  at	  12,000	  rpm	  and	  4	  °C.	  	  
The	   supernatant	   was	   then	   combined	   with	   4	   mL	   of	   HisPur™	   Ni-­‐NTA	   Resin	  
(Thermo	  SCIENTIFIC)	  that	  had	  been	  pre-­‐equilibrated	  and	  re-­‐suspended	  using	  bead	  
binding	  buffer	  (50	  mM	  KPi	  buffer	  pH	  7.5,	  5	  mM	  imidazole,	  300	  mM	  KCl,	  5%	  glycerol,	  
5	  mM	  β-­‐mercaptoethanol).	  	  Binding	  was	  performed	  at	  4	  °C	  with	  gentle	  rocking	  for	  2	  
hours.	   The	   slurry	   was	   then	   allowed	   to	   flow	   over	   an	   Econo-­‐Column®	  
chromatography	  column	  1.5x10	  cm	  (BioRad).	  The	  column	  was	  washed	  using	  buffer	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containing	   2	   mM	   imidazole.	   Fractions	   were	   collected	   using	   elution	   buffer	   with	  
different	  imidazole	  concentrations.	  	  
Fractions	   were	   analyzed	   on	   a	   10%	   SDS-­‐PAGE	   gel	   to	   observe	   the	   purified	  
protein.	  Fractions	  containing	  the	  protein	  were	  pooled	  together	  and	  dialyzed	  against	  
dialysis	  buffer	  (30	  mM	  KPi	  buffer	  pH	  7.5,	  10	  mM	  MgCl2,	  0.1	  mM	  EDTA	  pH	  8.0,	  10%	  
glycerol,	   5	   mM	   β-­‐mercaptoethanol,	   5	   mM	   dithiothreitol	   (DTT))	   with	   two	   buffer	  
changes	  every	  3	  hours	  and	  a	   final	  overnight	  dialysis	  against	  buffer	  with	   increased	  
glycerol	  at	  a	  concentration	  of	  50%.	  
Protein	  concentration	  was	  measured	  using	  the	  Bradford	  assay.	  Samples	  were	  
prepared	   by	   adding	   2	   μL	   of	   protein	   to	   100	   μL	   of	   Coomassie	   Plus	   -­‐	   The	   Better	  
Bradford	   Assay™	   Reagent	   (Thermo	   SCIENTIFIC)	   followed	   by	   incubation	   for	   a	  
minimum	  of	  10	  minutes	  before	  measurement	  on	  the	  Thermo	  SCIENTIFIC	  Nanodrop	  
2000	   Spectrophotometer.	   Standard	   curve	   was	   plotted	   using	   a	   stock	   solution	   of	  
bovine	  serum	  albumin	  (BSA)	  at	  different	  concentrations	  ranging	  from	  0	  to	  2	  mg/mL.	  	  
	  
2.3.	   Production	   of	   tRNA	   Through	   in	   vitro	   Transcription	   Using	   T7	   RNA	  
Polymerase	  
	   The	   plasmid	   ptDNAleu14(Mursinna	   and	  Martinis	   2002)	  which	   encodes	   the	  
gene	  for	  E.	  coli	  tRNALeuUAA	  was	  isolated	  and	  linearized	  using	  a	  BstN	  I	  digestion	  in	  a	  1	  
mL	  overnight	  reaction	  at	  60	  °C.	  Digested	  plasmid	  was	  then	  used	  as	  templates	  for	  in	  
vitro	  run-­‐off	  transcription(Sampson	  and	  Uhlenbeck	  1988)	  using	  T7	  RNA	  polymerase	  
at	  0.5	  μM	   in	   the	  presence	  of	  40	  mM	  tris(hydroxymethyl)aminomethane-­‐HCl	   (Tris)	  
pH	  8.0,	   30	  mM	  MgCl2,	   5	  mM	  DTT,	   0.01%	  Triton	  X-­‐100,	   ,	   2	  mM	  spermidine,	   50	  μg	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BSA,	  40	  μg/mL	  of	   	  E.	  coli	  pyrophosphatase	  (Sigma),	  7.5	  mM	  each	  of	  ATP,	  GTP,	  CTP	  
and	  UTP	  and	  0.5	  μM	  T7	  RNA	  polymerase.	  The	  reaction	  was	  incubated	  at	  37	  °C	  for	  4	  
hours.	  	  
After	  completion	  of	  reaction	  an	  equal	  volume	  of	  dye	  lite	  (bromophenol	  blue	  
1%	   and	   xylene	   cyanol	   1%	   in	   7	   M	   urea	   and	   20	   mM	   EDTA)	   was	   added	   and	   the	  
resulting	  solution	  was	  loaded	  on	  a	  10%	  polyacrylamide	  gel	  that	  contained	  7	  M	  urea.	  
The	   tRNA	  band	  was	   identified	   based	   on	  UV	   shadowing	   at	   254	  nm	  on	   a	   PEI	   plate.	  
This	   band	   was	   extracted	   and	   then	   crushed	   and	   soaked	   with	   tRNA	   elution	   buffer	  
(200	  mM	  potassium	  acetate	  pH	  5.4	  and	  10	  mM	  EDTA).	  	  
Elutions	   were	   collected	   through	   centrifugation	   using	   a	   clinical	   centrifuge	  
followed	   by	   filtration	   on	   BioRad	   column.	   The	   filtered	   elutions	   were	   then	   pooled	  
together	  and	  ethanol	  precipitated	  and	  resuspended	  in	  10	  mM	  HEPES	  buffer,	  0.1	  mM	  
EDTA.	  Concentrations	  were	  determined	  by	  A260	  measurement	  made	  on	  the	  Thermo	  
SCIENTIFIC	  Nanodrop	  2000	  Spectrophotometer.	  
	  
2.4.	  Enzyme	  Assays	  
2.4.1. Aminoacylation	  Assay	  
Aminoacylation	  was	  carried	  out	  as	  described(Mursinna	  and	  Martinis	  2002)	  
with	   the	   following	   exceptions.	   Each	   aminoacylation	   reaction	   contained	   60	   mM	  
HEPES	   buffer	   pH	   7.5,	   10	   mM	  MgCl2,	   50	   mM	  MgCl2,	   2	   mM	   DTT,	   4	   μM	   tRNALeu	  or	  
analogues,	   60	   μM	   L-­‐[14C]-­‐leucine	   (329	   μCi/mmol)	   and	   4mM	   ATP.	   Aminoacylation	  
was	  initiated	  by	  addition	  of	  50	  nM	  enzyme	  to	  the	  reaction	  mixture.	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Reaction	   was	   quenched	   at	   specific	   time	   points	   by	   spotting	   5	   μL	   of	   the	  
reaction	  on	  filter	  pads	  (Whatman)	  that	  had	  been	  pre-­‐soaked	  in	  10%	  trichloroacetic	  
acid	  (TCA).	  Filter	  pads	  were	  washed	  three	  times	  with	  5%	  TCA	  for	  8	  min	  each	  and	  
then	   a	   final	   8	  min	  wash	   in	   95%	   ethanol,	   followed	   by	   air-­‐drying.	   Dried	   pads	  were	  
transferred	  to	  20	  mL	  scintillation	  vials	  with	  3	  mL	  of	  ScintiSafe™	  Econo	  F	  scintillation	  
cocktail	   (Fisher	   Scientific).	  Quantitation	  was	   carried	   out	   using	   a	  Beckman	  LS6500	  
multipurpose	  scintillation	  counter.	  
	  
2.4.2. ATP	  Hydrolysis	  Assay	  
 Reactions	  containing	  50	  mM	  HEPES	  buffer	  pH	  7.5,	  10	  mM	  MgCl2,	  5	  mM	  DTT,	  	  
5	  μM	   tRNALeu	  or	   its	  analogue,	  5	  mM	  amino	  acid,	  18	  μM	  [α-­‐32P]-­‐ATP	  (15	  Ci/mmol)	  
and	  1	  μM	  protein	  enzyme	  was	  used	   to	   initiate	   the	   reaction.	  Aliquots	  of	  2	  μL	  were	  
spotted	   on	   cellulose	   PEI	   plates	   that	   were	   pre-­‐run	   in	   water.	   The	   TLC	   plates	   were	  
developed	  in	  750	  mM	  KH2PO4	  pH	  3.5	  and	  air-­‐dried	  (Splan	  et	  al.	  2008).	  Radiolabelled	  
bands	   were	   detected	   by	   exposing	   a	   FUJIX	   BAS	   1000	   phosphoimager	   screens	  
(FUJIFILM	  Medical	   Systems	  USA	   Inc.)	   and	  visualized	  using	   a	   Storm	  840	  Molecular	  
Dynamics	  Imager	  (GE	  Healthcare,	  Piscataway,	  NJ).	  
	  
2.5.	  RNA	  Analysis	  Through	  Polyacrylamide	  Gel	  Electrophoresis	  	  
The	  purity	   of	   tRNA	  was	   evaluated	   by	   observing	   the	   banding	   pattern	   on	   an	  
analytical	   polyacrylamide	   gel.	   E.	   coli	   tRNALeu	   is	   87	   nt	   long	   hence	   an	   8%	  
polyacrylamide	   gel	   that	   contained	   7	   M	   urea	   and	   had	   a	   thickness	   of	   0.4	   mm	  was	  
chosen	  (Table	  II.I).	  A	  1:1	  mixture	  of	  bromophenol	  blue	  and	  xylene	  cyanol	  was	  used	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as	   loading	   dye.	   The	   samples	   were	   electrophoresed	   at	   a	   constant	   current	   of	   20	  
mAmps.	   A	   conducting	   plate	  was	   attached	   to	   the	   back	   plate	   of	   the	   gel	   in	   order	   to	  
consistently	  electrophorese	  the	  samples	  at	  higher	  temperature	  of	  ~	  60°C.	  The	  tRNA	  
bands	   were	   visualized	   by	   overnight	   staining	   of	   the	   analytical	   gel	   using	   0.2%	   of	  
Stains-­‐All	   (Sigma-­‐Aldrich)	  dissolved	   in	   formamide	  solution	  diluted	  with	  water	   in	  a	  
1:1	   ratio.	   Stains-­‐All	   is	   light	   sensitive	   hence	   destaining	  was	   achieved	   through	   light	  
exposure	  of	  the	  gel	  2	  hours	  by	  placing	  it	  on	  a	  light	  box.	  	  
	  
Table	  2.1:	  Correlation	  between	  concentration	  of	  acrylamide	  and	  RNA	  banding	  
pattern	  as	  observed	  on	  an	  analytical	  gel.	  
%	  Acrylamide	   Xylene	  cyanol	   Bromophenol	  blue	  
8%	   70-­‐80	  nt	   19	  nt	  
10%	   	  	  	  	  	  	  	  55	  nt	   12	  nt	  
15%	   	  35-­‐38	  nt	   10	  nt	  
20%	   	  	  	  	  	  	  	  28	  nt	   	  	  8	  nt	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   All	   tRNA	  molecules	   are	   characterized	   by	   the	   3’-­‐terminal	   CCA	   end,	  wherein	  
the	   A76	   residue	   is	   critical	   for	   aminoacylation	   reaction.	   The	   essentiality	   of	   the	   A76	  
residue	  makes	  it	  an	  important	  tool	  that	  has	  been	  used	  to	  establish	  the	  mechanism	  of	  
tRNA	  charging	  by	  AARSs	  (Alexander	  et	  al.	  2010;	  Bruice	  and	  Fife	  1962;	  Minajigi	  and	  
Francklyn	  2008;	  Nordin	  and	  Schimmel	  2002;	  Sprinzl	  2006;	  Taiji	  et	  al.	  1983).	  Early	  
experiments	   performed	   using	   the	   2’	   or	   3’ deoxy modified tRNA A76	   analogues,	  
were	   particularly	   instructive	  when	   establishing	   the	   2’ vs 3’ hydroxyl group bias 
between the two AARS classes (Sprinzl and Cramer 1975b).  
 The	  intact	  3’	  terminus	  of	  the	  tRNA	  is	  essential	  for	  its	  role	  in	  transfer	  of	  amino	  
acids.	  In	  case	  of	  isoleucyl	  tRNA	  synthetase,	  a	  type	  I	  synthetase	  it	  was	  observed	  that	  
after	  the	  initial	  aminoacyl	  transfer	  to	  2’	  hydroxyl	  group	  of	  the	  terminal	  adenosine,	  a	  
transfer	   to	  3’	  hydroxyl	  group	  was	  necessary	  before	  editing	  can	  occur	   (Nordin	  and	  
Schimmel	  2002).	  In	  another	  example	  it	  was	  implicated	  that	  the	  interaction	  of	  the	  the	  
2’	  hydroxyl	  group	  of	  the	  terminal	  adenosine	  of	  the	  tRNA	  with	  a	  histidine	  residue	  of	  
threonyl	   tRNA	   synthetase,	   a	   type	   II	   synthetase,	   was	   essential	   for	   the	   correct	  
positioning	  of	   the	  3’	   end	  of	   the	   tRNA	   in	   the	  active	   site	  of	   the	   synthetase	   (Minajigi	  
and	  Francklyn	  2008).	  
Considerable	   effort	   has	   been	   expended	   for	   developing	   techniques	   to	  
manipulate	   the	   3’	   terminus	   of	   the	   tRNA.	   A	   key	   component	   common	   to	   these	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methods	  is	  use	  of	  the	  nucleotidyl	  transferase	  enzyme,	  commonly	  known	  as	  the	  CCA-­‐
adding	  enzyme	  (Betat	  and	  Morl	  2015;	  Cho	  et	  al.	  2003;	  Deutscher	  1982;	  Tomita	  et	  al.	  
2004;	   Xiong	   and	   Steitz	   2006).	  Many	   eukaryotes	   and	   prokaryotes	   do	   not	   have	   the	  
CCA-­‐end	   of	   tRNA	   encoded	   into	   their	   genome.	   Thus,	   the	   CCA	   addition	   forms	   an	  
important	   post-­‐transcriptional	   modification	   in	   these	   organisms.	   Organisms	   that	  
encode	   the	   tRNA	   CCA-­‐end	   still	   use	   CCA-­‐adding	   enzyme	   in	   a	   housekeeping	   role	   of	  
maintaining	  the	  intact	  3’-­‐terminus	  of	  tRNA.	  	  
The	  CCA-­‐adding	  enzyme	  is	  similar	  to	  poly-­‐A	  polymerase	   family	  of	  enzymes.	  
However,	   this	   enzyme	   is	   a	   unique	   type	   of	   polymerase	   as	   it	   carries	   out	   a	   defined	  
sequence	   of	   primer	   extension	   in	   a	   template	   independent	   manner	   (Tomita	   et	   al.	  
2004).	   The	   reaction	   occurring	   at	   the	   active	   site	   of	   the	   enzyme	   proceeds	  with	   the	  
release	  of	  a	  pyrophosphate	  molecule	  with	  every	  nucleotide	  addition	  (Fig.	  3.1).	  Most	  
methods	  for	  synthesis	  of	  tRNA	  analogues	  make	  use	  of	  this	  reaction	  and	  its	  reversible	  
nature.	  
	  
Fig.	   3.1.	   Reaction	   catalyzed	   by	   CCA-­‐adding	   enzyme.	   Stepwise	   addition	   of	   two	  
molecules	  of	  CTP	  (green)	  followed	  by	  an	  ATP	  molecule	  (blue)	  occurs	  with	  the	  release	  
of	  a	  pyrophosphate	  (PPi)	  molecule	  at	  each	  step.	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3.2.	  One-­‐Step	  Reaction	  
3.2.1.	  	  ATP	  analogue	  exchange	  reaction	  	  
In	   a	   one-­‐step	   reaction	   adapted	   from	  Minajigi	   and	   Francklyn	   (Minajigi	   and	  
Francklyn	   2008)	   the	   3’-­‐terminal	   adenosine	   was	   cleared	   and	   replaced	   with	   a	  
modified	   nucleotide.	   Each	   reaction	   combined	   15	   μM	   in	   vitro	   transcribed	   E.	   coli	  
tRNALeuUAA,	   6	   mM	  modified	   ATP	   and	   5	   μM	   E.	   coli	   CCA-­‐adding	   enzyme	   incubation	  
thereof	  20	  mM	  glycine	  at	  pH	  9.0,	  20	  mM	  MgCl2,	  1	  mM	  PPi	  at	  37	  °C	  for	  4	  hours.	  	  
Protein	   was	   removed	   by	   extraction	   with	   equal	   volume	   of	  
acid:phenol:chloroform,	  pH	  4.5	  (with	  IAA,	  125:24:1)	  was	  added	  and	  the	  mixture	  was	  
mixed	  by	  vortexing	  for	  	  	   	   	  15	  sec	  and	  centrifuged	  at	  10,000	  g	  for	  1	  min.	  	  The	  upper	  
aqueous	  layer	  was	  transferred	  to	  a	  new	  tube	  with	  addition	  of	  1/10	  volume	  of	  3	  M	  
sodium	  acetate,	  pH	  5.2	  and	  2	  volume	  of	  100%	  ethanol	  then	  kept	  at	  -­‐80	  °C	  over	  night.	  	  
The	  precipitated	  tRNA	  was	  pelleted	  at	  20,000	  g	   for	  30	  min	  at	  4	  °C	  and	  washed	  by	  
70%	  ethanol	  at	  20,000	  g	  for	  10	  min	  at	  4	  °C.	  	  The	  tRNA	  pellet	  was	  vacuum-­‐dried	  for	  
20	  min	  and	  dissolved	   in	  water.	   	   The	   final	   concentration	  was	  determined	  using	   an	  
extinction	  coefficient	  of	  871,000	  M-­‐1	  cm-­‐1.	  
	  
3.2.2.	  	  ATP	  analogue	  addition	  to	  ΔA76	  tRNALeu	  
A	   truncated	   tRNA	   missing	   the	   terminal	   3’	   adenosine	   was	   generated	   by	   in	  
vitro	  transcription	  to	  facilitate	  efficient	  addition	  of	  modified	  bases.	  In	  a	  reaction	  that	  
was	   adopted	   from	   Nordin	   and	   Schimmel,	   6	   mM	   ATP	   analogues	   (i.e.	   2’-­‐dATP,	   3’-­‐
dATP,	  3’-­‐OMe-­‐ATP	  or	  3’-­‐NH2-­‐ATP)	  were	  combined	  with	  15	  μM	   in	  vitro	   transcribed	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E.	  coli	  ΔA76	  tRNALeu	  and	  5	  μM	  E.	  coli	  CCA-­‐adding	  enzyme	  in	  20	  mM	  Tris	  pH	  8.5	  and	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Fig : Scheme for preparing E. Coli ΔA76 tRNA
Leu using custom designed oligonucleotides 
Fig.	   3.2.	   Scheme	   for	   preparing	   using	   custom	   designed	   oligonucleotides.	   The	  
oligonucleotides	  have	  been	  color-­‐coded	  to	  represent	  base	  complementarity.	  The	  zoom	  in	  
shows	  the	  Bbs	  I	  recognition	  site.	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Design	  and	  production	  of	  ΔA76	  tRNALeu:	  An	  in	  vitro	  transcribed	  tRNA	  that	  
was	   lacking	   the	   3’	   adenosine	   was	   developed	   (Fig.	   3.2)	   to	   facilitate	   efficient	  
production	  of	  tRNAs	  with	  modified	  ends	  in	  a	  one	  step	  reaction.	  The	  ΔA76	  tRNALeuUAA	  
was	  designed	  using	  the	  gene	  construction	  method	  originally	  described	  by	  Normanly	  
(Normanly	  et	  al.	  1986),	  DNA	  oligo	  nucleotides	  were	  designed	  to	  span	  the	  entire	  gene	  
sequence	  of	  E.	  coli	  tRNALeu	  (Table	  2).	  Each	  was	  first	  3’end	  labeled	  with	  phosphate	  by	  
combining	  4	  μM	  DNA	  oligos	  and	  3	  U	  of	  T4	  polynucleotide	  kinase	  in	  25	  μL	  reactions	  
with	   commercial	   buffer,	   the	   reactions	  were	   incubated	   at	   37	   °C	   for	   1.5	   hours	   and	  
then	  the	  enzyme	  was	  heat	  killed	  at	  65	  °C	  for	  20	  min.	  The	  3’	  end	  labeled	  oligos	  were	  
annealed	   at	   0.4	   μM	   in	   a	   50	  μL	   reaction	  with	   addition	  of	  T7	   top	   and	  T7	   btm	  oligos	  
(Table	   3.1).	   Annealed	   oligos	   at	   a	   concentration	   of	   0.1	   pmol/μL	  were	   ligated	  with	  
EcoR	   I	   (NEB,	   Beverly,	   MA)	   and	   Pst	   I	   (NEB,	   Beverly,	   MA)	   double	   digested	   linear	  
pUC18	  vector	  (NEB,	  Beverly,	  MA)	  at	  0.01	  pmol/μL	  using	  20	  U/μL	  T4	  DNA	  ligase	  to	  
obtain	  the	  plasmid	  pABΔA76tRNALeu.	  	  
New	  plasmid	  pABΔA76tRNALeu	  was	  used	  to	  transform	  E.	  coli	  DH5α	  cells	  by	  
heat	  shock.	  Transformants	  were	  selected	  on	  L.B.	  containing	  100	  μg/	  mL	  ampicillin	  
and	  colonies	  were	  screened	  by	  PCR.	  Each	  colony	  was	  added	  to	  50	  μL	  of	  sterile	  water,	  
vortexed	  and	  amplified	  via	  PCR	  to	  identify	  the	  insert	  based	  on	  length.	  The	  PCR	  was	  
carried	   out	   using	   FOR88	   and	   Seq3A	   primers	   at	   2	   μM	   using	   0.02	   U/μL	   of	   Vent	  
Polymerase	  (NEB,	  Beverly,	  MA)	  on	  BioRad	  C1000	  Touch™	  Thermal	  Cycler	  using	  the	  
program	  1	  min	  at	  94	   °C,	  30	  sec	  at	  55	   °C	   followed	  by	  40	  sec	  at	  72	   °C.	  This	  cycle	   is	  
repeated	  30	  times	  followed	  by	  a	  final	  incubation	  of	  5	  min	  at	  72	  °C.	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Table 3.1: Oligonucleotides Used for designing ΔA76 tRNALeu. 
Oligonucleotide Sequence Use 
T7 top AATTCTAATACGACTCA 
Designing 
pABΔA76tRNA 
T7 btm TATAGTGAGTCGTATTAG 
Designing 
pABΔA76tRNA 
FOR 88 GCTGGCGAAAGGGGGATGTGCTG 
Sequencing and  
PCR amplification of 
template 
Seq 3A GCTCGCCGCAGCCGAACGACCGAGCG 
Sequencing and  
PCR amplification of 
template 
Eco TAA_1 CTATAGCCCGGATGGTGGAATC 
Designing 
pABΔA76tRNA 
Eco TAA_2 GGTAGACACAAGGGATTTAAAATCCCTC 
Designing 
pABΔA76tRNA 
Eco TAA_3A GCTCGCCGCAGCCGAACGACCGAGCG 
Designing 
pABΔA76tRNA 
Eco TAA_3B GGTTCAAGTCCCGCTC 
Designing 
pABΔA76tRNA 
Eco TAA_4 CGGGTACCAGGTCTTCTGCA 
Designing 
pABΔA76tRNA 








Eco TAA_7A GAAGACCTGGTACCCGGAGCGGGACTT 
Designing 
pABΔA76tRNA 
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3.3.	  Two-­‐Step	  Reaction	  
	   The	   first	   step	   involves	   obtaining	   tRNA	  molecule	   missing	   the	   CCA-­‐end.	   For	  
this	  reaction	  15	  μM	  in	  vitro	  transcribed	  E.	  coli	  tRNALeuUAA,	  was	  combined	  with	  5	  μM	  
E.	  coli	  CCA-­‐adding	  enzyme	  and	  10	  mM	  PPi	  was	  incubated	  at	  37	  °C	  for	  4	  hours	  in	  the	  
presence	  of	  20	  mM	  glycine	  at	  pH	  9.0,	  20	  mM	  MgCl2.	  The	  tRNA	  thus	  obtained	  was	  gel	  
purified	   and	   used	   in	   the	   second	   step	   to	   add	   the	   CCA	   end.	   This	   reaction	   was	  
performed	  using	  2	  µM	  of	   the	  purified	  tRNA	  and	  reacting	   it	  with	  CTP	  and	  ATP	  at	  1	  
mM	  each	  using	  50	  nM	  E.	  coli	  CCA	  adding	  enzyme.	  The	  reaction	  was	  then	  incubated	  
at	  37	  °C	  for	  4	  hours	  in	  the	  presence	  of	  the	  same	  buffer	  that	  was	  used	  in	  the	  first	  step.	  
	  
3.4.	  Results	  
	   The	   efficiency	   with	   which	   the	   analogue	   exchange	   occurred	   was	   first	  
evaluated	   using	   an	   8%	   polyacrylamide	   gel	   that	   contained	   7	   M	   urea	   and	   had	   a	  
thickness	   of	   0.4	  mm	   (8%	  analytical	   gel).	   The	   advantage	   of	   using	   this	  method	  was	  
that	   single	   nucleotide	   resolution	   could	   be	   achieved.	   This	   method	   is	   an	   excellent	  
visual	   tool	   for	   a	   qualitative	   determination	   of	   tRNA	   analogue	   integrity	   over	   the	  
course	  of	  any	  given	  preparatory	  method.	  
Next	   the	   purified	   tRNA	   analogues	   were	   subjected	   to	   aminoacylation	   assay	  
with	  E.	   coli	  LeuRS	   to	   further	   determine	   the	   success	   of	   the	   synthesis	  method.	   The	  
LeuRS	  enzyme	  is	  class	  I,	  thus	  aminoacylation	  would	  occur	  at	  the	  2’OH	  position	  (Fig.	  
3.3).	  The	  2’dA76tRNA	  is	  chosen	  as	  a	  control	  since	  this	  tRNA	  analogue	  is	  incapable	  of	  
aminoacylation	  as	  it	  is	  missing	  the	  2’OH	  group.	  
	   	  





	   	  
Fig.	  3.3.	  Aminoacylation	  reaction	  by	  AARS	  and	  the	  effect	  of	  the	  3’OH	  group	  
of	   terminal	   A76.	  Electrophilicity	  of	   the	  attacking	  2’O	  atom	  is	   influenced	  by	   the	  
hydrogen	  bonding	   capability	  of	   the	   substituent	  at	   the	  3’ position	  on	   the	   ribose	  
ring	  of	  the	  terminal	  A76	  of	  the	  tRNA.	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The	  one-­‐step	  ATP-­‐analogue	  exchange	  reaction	  was	  first	  employed	  on	  a	  trial	  
basis	  for	  the	  preparation	  3’	  dA76	  tRNA	  and	  2’ dA76	  tRNA.	  The	  tRNAs	  obtained	  were	  
87	   nucleotides	   and	   showed	  no	   signs	   of	   degradation	  when	   compared	  with	   the	   full	  
length	  tRNA	  on	  an	  8%	  analytical	  gel.	  However,	  when	  these	  tRNAs	  were	  subjected	  to	  
aminoacylation	   assay	   both	   3’	   dA76	   tRNA	   and	   2’ dA76	   tRNA	   showed	   charging	   at	  
similar	  levels,	  comparable	  to	  but	  slightly	  lower	  than	  that	  of	  the	  full	  length	  tRNA	  (Fig.	  
3.4).	   This	  was	   contrary	   to	   the	   expectation	   that	  2’ dA76	   tRNA	   is	   unchargeable.	   The	  
observation	  indicated	  the	  limitation	  of	  this	  method	  for	  preparation	  of	  analogues	  E.	  
coli	  tRNALeuUAA.	  
	  




















Full	  length	  tRNA	  
3'	  dA76	  tRNA	  
2'	  dA76	  tRNA	  
Fig.	   3.4.	   Aminoacylation	   for	   tRNA	   analogues	   obtained	   from	   ATP	   analogue	  
exchange	  reaction.	  Aminoacylation	  reaction	  was	  carried	  out	  using	  1	  µM	  tRNA	  and	  
50	  nM	  E.	  coli	  LeuRS	  enzyme.	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Given	  the	  reversibility	  of	  the	  reaction	  by	  CCA-­‐adding	  enzyme	  in	  the	  presence	  
of	  pyrophosphate,	  it	  was	  explored	  as	  an	  agent	  for	  obtaining	  tRNA	  missing	  the	  CCA-­‐
end.	   It	   was	   observed	   that	   in	   the	   presence	   of	   5	   mM	   PPi	   a	   faint	   lower	   band	  
corresponding	   to	   a	   tRNA	  molecule	  missing	   the	   CCA-­‐end	  was	   obtained.	   Increasing	  
the	  concentration	  of	  PPi	  to	  10	  mM	  primarily	  resulted	  in	  a	  tRNA	  molecule	  missing	  the	  
CCA	  end	  (Fig.	  3.5.A).	  It	  was	  observed	  that	  in	  the	  absence	  of	  ATP	  the	  enzyme	  acted	  as	  
a	   polyC	   polymerase	   adding	   a	   CTP	   molecule	   instead	   (Betat	   and	   Morl	   2015)	   (Fig.	  
3.5.B).	  
	   The	  final	  method	  that	  was	  tested	  involved	  a	  one-­‐step	  ATP	  analogue	  addition	  
to	  ΔA76	  tRNALeu.	  As	  has	  been	  observed	  previously	  the	  different	  ATP	  analogues	  have	  
different	  efficiency	  of	  addition	  using	  CCA-­‐adding	  enzyme	  (Cho	  et	  al.	  2003).	  Similar	  
results	  were	  obtained	  when	  the	  time	  course	  for	  addition	  of	  ATP,	  2’dATP,	  3’NH2ATP	  
and	  3’dATP	  was	  followed	  (Fig.	  3.6.A).	  When	  the	  CCA-­‐adding	  reaction	  was	  allowed	  to	  
proceed	   for	   4	   hours	   complete	   addition	   was	   observed	   for	   all	   ATP	   analogues	   (Fig.	  
3.6.B).	   The	   purified	   tRNA	   analogues	  were	   then	   subjected	   to	   aminoacylation	   assay	  
using	   the	  E.	  coli	   	   LeuRS.	  As	  per	   expectation	   the	  2’dA76tRNA,	  ddA76tRNA	  and	  ΔA76	  
tRNA	   were	   unchargeable.	   The	   full	   length,	   A76tRNA	   and	   3’OMeA76tRNA	   showed	  
similar	   aminoacylation	   trends	   and	   plateaued	   after	   5	   minutes.	   However,	   the	  
3’NH2A76tRNA	  showed	  a	  much	  slower	  rate	  of	  aminoacylation	  (Fig.	  3.7).	  This	  could	  
likely	  be	  attributed	  to	  the	  fact	  that	  at	  near	  neutral	  pH	  the	  amine	  group	  on	  the	  tRNA	  
may	  be	  present	  as	  a	  zwitterion	  form	  that	  impedes	  the	  rate	  of	  aminoacylation.	  
	  
	  




	   	  
A.	  
B.	  
Fig.	  3.5.	  Analysis	  of	  tRNA	  from	  two-­‐step	  reaction.	  The	  time	  course	  for	  removal	  of	  
the	  terminal	  CCA-­‐end	  for	  15	  µM	  E.	  coli	  tRNALeuUAA	  in	  the	  presence	  of	  5	  µM	  E.	  coli	  CCA	  
adding	  enzyme	  and	  pyrophosphate	  (A).	  Either	  CTP	  (1	  mM)	  or	  CTP	  and	  ATP	  (1	  mM	  
each)	  is	  added	  back	  to	  2	  µM	  E.	  coli	  tRNALeuUAA	  (obtained	  after	  CCA-­‐end	  removal	  using	  
from	  10	  mM	  PPi)	  in	  the	  presence	  of	  50	  nM	  E.	  coli	  CCA	  adding	  enzyme	  (B).	  











Fig.	  3.6.	  Addition	  of	  ATP	  analogue	   to	  ΔA76	   tRNALeu.	  An	  8%	  analytical	  gel	  showing	  
the	  time	  course	  of	  analogue	  addition	  (A)	  and	  analysis	  of	  purified	  analogues	  (B).	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3.5.	  Discussion	  
The	  tRNA	  molecules	  based	  on	  their	  origin	  show	  preference	  towards	  certain	  
methods	  of	  analogue	  preparation.	  While	  using	  in	  vitro	  transcribed	  tRNA	  using	  the	  a	  
one-­‐step	  ATP	  analogue	  addition	  to	  ΔA76	  tRNALeu	  seems	  to	  be	  the	  method	  of	  choice.	  
This	   method	   ensures	   complete	   homogeneity	   of	   product	   and	   is	   free	   of	   any	  
contamination	   from	  ATP.	  Additionally,	   given	   the	   control	  on	  designing	  of	   the	   tRNA	  
transcript	  this	  method	  in	  principal	  can	  be	  applied	  universally	  to	  obtain	  any	  desired	  
in	  vitro	  tRNA	  analogue.	  
Fig.	  3.7.	  Aminoacylation	  activity	  for	  tRNA	  analogues	  obtained	  through	  addition	  
to	  ΔA76	  tRNALeu.	  The	  tRNA	  analogues	  A76tRNA	  (blue),	  2’dA76tRNA	  (red),	  dd	  A76tRNA	  
(green),	  3’NH2A76tRNA	  (purple),	  3’OMeA76tRNA	  (cyan)	  and	  Full	  length	  tRNA	  (orange)	  
at	  4	  µM	  were	  aminoacylated	  using	  50	  nM	  E.	  coli	  LeuRS	  enzyme.	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Chapter	  4:	  CP1	  Domain	  Dictates	  tRNA	  Dependence	  of	  Pre-­‐transfer	  




The	   fidelity	   of	   aminoacylation	   by	   the	   synthetases	   is	   ensured	   through	   the	  
presence	  of	  the	  editing	  mechanism.	  LeuRS	  amongst	  other	  class	  I	  a	  synthetases	  has	  
an	  appended	  CP1	  domain,	  that	  is	  responsible	  for	  post-­‐transfer	  editing.	  The	  absence	  
of	   the	   CP1	   domain	   in	  Mycoplasma	  mobile	  has	   been	   shown	   to	   result	   in	   statistical	  
mutations	  in	  this	  organism.	  It	  was	  also	  observed	  that	  the	  addition	  of	  the	  CP1	  domain	  
to	  the	  Mycoplasma	  mobile	  leuRS	  resulted	  in	  an	  increased	  fidelity	  of	  this	  enzyme.	  The	  
addition	   of	   the	   CP1leu	   or	   CP1Ile	   in	   particular	   resulted	   in	   an	   increase	   in	   the	  
discrimination	  factor	  (Boniecki	  and	  Martinis	  2012).	  It	  appeared	  that	  the	  presence	  of	  
CP1	  domain	  might	  influence	  adenylate	  stability	  in	  the	  synthetic	  site.	  
Between	   the	   two	  editing	  mechanisms	  depending	  on	   the	  origin	  of	   the	   leuRS	  
the	  enzyme	  can	  show	  a	  preference	  for	  one	  mechanism	  over	  the	  other	  (Englisch	  et	  al.	  
1986).	   The	   standard	   amino	   acids	   that	   confound	   the	   LeuRS	   active	   site	   include	  
isoleucine,	   valine	   and	  methionine	   (Karkhanis	   et	   al.	   2007b).	   For	   a	   given	   leuRS	   the	  
choice	  between	  the	  amino	  acids	  could	  be	  dependent	  on	   the	  amino	  acid	   identity.	   It	  
has	  been	  observed	  in	  the	  case	  of	  yeast	  cytoplasmic	  leuRS	  that	  while	  isoleucine	  can	  
be	  edited	  via	  the	  post-­‐transfer	  mechanism,	  the	  editing	  of	  methionine	  proceeds	  via	  a	  
mechanism	  other	  than	  the	  post-­‐transfer	  editing	  (Sarkar	  and	  Martinis	  2011).	  
The	   non-­‐standard	   amino	   acid,	   norvaline	   poses	   a	   threat	   to	   LeuRS	   fidelity	  
(Cvetesic	   et	   al.	   2014;	  Karkhanis	   et	   al.	   2007b).	  The	   incorporation	  of	  norvaline	   into	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proteins	  is	  a	  function	  of	  the	  ratio	  of	  concentration	  of	  norvaline/leucine.	  As	  this	  ratio	  
increases	   there	   is	  greater	  availability	  of	  misaminoacylated	  norvalyl-­‐tRNALeu	  during	  
protein	  synthesis.	  	  
	  
Norvaline	   is	   produced	   as	   a	   byproduct	   during	   cellular	   leucine	   metabolism.	  
Under	  normal	   growth	   conditions,	   concentration	  of	   norvaline	   is	   significantly	   lower	  
than	  leucine	  and	  there	  is	  no	  observed	  norvaline	  incorporation	  into	  cellular	  proteins.	  
However,	  when	  E.	  coli	  cells	  are	  subjected	  to	  stress	  as	  over	  expression	  of	  leucine	  rich	  
proteins,	   the	   additional	   leucine	   demand	   causes	   an	   accumulation	   of	   norvaline	  
(Apostol	  et	  al.	  1997).	  Additionally,	  increase	  in	  levels	  of	  norvaline	  has	  been	  observed	  
in	  E.	  coli	  under	  conditions	  of	  limited	  oxygen	  (Soini	  et	  al.	  2008).	  	  
The	  E.	  coli	   leuRS	   is	   known	   to	   edit	  mainly	   through	   the	  post-­‐transfer	   editing	  
mechanism	  (Englisch	  et	  al.	  1986).	  However,	  in	  the	  absence	  of	  the	  CP1	  domain	  it	  was	  
observed	   that	   the	  E.	   coli	   leuRS	   CP1	   deletion	  mutant	   (leuRSΔCP1)	   still	  maintained	  
Fig.	   4.1.	   Standard	   and	   non-­‐standard	   amino	   acids	   encountered	   by	   LeuRS.	  The	  
standard	  and	  non-­‐standard	  amino	  acids	  are	  represented	  in	  the	  blue	  and	  green	  boxes	  
respectively.	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fidelity.	   It	  was	   hypothesized	   that	   an	   inherent	   pre-­‐transfer	   editing	  mechanism	  had	  
been	  activated	  at	   the	  synthetic	  site	  of	   the	  enzyme	  (Boniecki	  et	  al.	  2008).	  Here,	  we	  
investigate	  the	  role	  of	  the	  CP1	  domain	  from	  the	  E.	  coli	  leuRS	  in	  pre-­‐transfer	  editing.	  
We	   further	   determine	   the	   influence	   that	   amino	   acid	   identity	   can	   have	   on	   the	  
preference	  between	  the	  two	  editing	  mechanisms.	  
	  
4.2.	  Methods	  
	   The	  materials	  and	  methods	  used	  are	  same	  as	   those	  described	   in	  chapter	   II.	  
The	   tRNA	   analogues	   used	  were	   prepared	   as	   per	   the	   one	   step	   reaction	  method	   of	  
ATP	  analogue	  addition	  to	  ΔA76	  tRNALeu	  listed	  in	  chapter	  III.	  
4.3.	  Results	  
The	   E.	   coli	   LeuRS	   fidelity	   is	   challenged	   by	   non-­‐cognate	   amino	   acids,	   in	  
particular	  isoleucine	  and	  norvaline	  (Cvetesic	  et	  al.	  2014;	  Karkhanis	  et	  al.	  2007a).	  E.	  
coli	  LeuRS	  is	  known	  to	  primarily	  edit	  through	  a	  post-­‐transfer	  mechanism	  (Englisch	  
et	   al.	   1986).	   However,	   it	   has	   been	   observed	   that	   a	   post-­‐transfer	   editing	   deficient	  
mutant,	  LeuRSΔCP1	  maintains	  the	  aminoacylation	  fidelity.	  It	  is	  hypothesized	  in	  this	  
mutant	   enzyme	   in	   the	   absence	   of	   the	   CP1	   hydrolytic	   domain	   an	   inherent	   pre-­‐
transfer	  editing	  activity	  has	  been	  activated	  (Boniecki	  et	  al.	  2008).	  Here	  we	   further	  
investigate	  the	  editing	  mechanism	  at	  the	  synthetic	  site	  of	  E.	  coli	  LeuRS.	  In	  this	  study	  
a	   tRNA	   analogue	   that	   lacked	   the	   terminal	   A76	   has	   been	   designed	   using	   oligo	  
recombineering	  a	  BbsI	  back	  digestion	  to	  obtain	  the	  ΔA76tRNA	  (Nordin	  and	  Schimmel	  
2002).	  This	  tRNA	  analogue	  lacks	  the	  terminal	  A76	  necessary	  for	  aminoacylation	  and	  
thus	  is	  a	  good	  tool	   for	  studying	  the	  effect	  of	  tRNA	  body	  on	  pre-­‐transfer	  editing.	  As	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expected	  the	  ΔA76tRNALeuUAA	  did	  not	  show	  any	  aminoacylation	  activity	  with	  the	  wild	  
type	   LeuRS.	   Under	   the	   same	   conditions	   in	   vitro	   transcribed	   tRNALeuUAA	   could	   be	  
charged	  completely	  by	  this	  enzyme	  (Fig.	  4.1	  B).	  
	  
We	   tested	   the	   ATP	   hydrolysis	   activity	   of	   the	   LeuRSΔCP1	   mutant	   in	   the	  
presence	  of	  the	  different	  amino	  acids.	  For	   leucine	  we	  observed	  an	  increase	   in	  ATP	  
hydrolysis	   only	   in	   the	   presence	   of	   full	   length	   tRNA.	   The	   ΔA76tRNA	   showed	   ATP	  
Fig.	   4.2.	   LeuRS	   aminoacylation.	   A.	   Aminoacylation	   of	   terminal	   adenosine	   of	   tRNA	  
(A76)	  with	  release	  of	  pyrophosphate	  (PPi)	  resulting	  in	  the	  formation	  of	  a	  charged	  tRNA.	  
B.	  Aminoacylation	  activity	  of	  full-­‐length	  tRNALeuUAA	  (	  	  )	  and	  ΔA76-­‐tRNALeuUAA	  (	  	  )	  by	  wild	  
type	   E.	   coli	   LeuRS.	   Aminoacylation	   was	   carried	   out	   using	   50	   nM	   LeuRS	   and	   4	   μM	  
tRNALeu.	  Error	  bars	  are	  based	  on	  each	  reaction	  repeated	  in	  triplicate.	  Absence	  of	  error	  
bars	  indicates	  the	  difference	  between	  the	  triplicates	  was	  small.	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hydrolysis	  at	  levels	  similar	  to	  the	  no	  tRNA	  and	  no	  tRNA/no	  amino	  acid	  control	  (Fig.	  
4.2	  A).	  This	  indicates	  the	  absence	  of	  leucyl	  adenylate	  hydrolysis	  at	  the	  synthetic	  site	  
of	   LeuRSΔCP1	   enzyme.	   The	   trend	   for	   ATP	   hydrolysis	   activity	   and	   AMP	   formation	  
observed	   for	   isoleucine	  was	   similar	   to	   that	   for	   leucine	   (Fig.	   4.2	  B).	   Increased	  ATP	  
Fig.	   4.3.	   Norvaline	   selectively	   stimulates	   pre-­‐transfer	   editing	   by	   E.	   coli	   LeuRS	  
ΔCP1.	   Reaction	  mixtures	   contained	   5	   μM	   	   tRNALeuUAA	   	   analogues	   and	   1	   μM	   LeuRS-­‐
ΔCP1.	   Consumption	   of	   ATP	   and	   AMP	   production	   are	   shown	   on	   the	   left	   and	   right	  
respectively	   in	   the	   presence	   of	   leucine	   (A),	   isoleucine	   (B)	   and	   norvaline	   (C).	  
Experiments	  included	  tRNALeuUAA	  (	  	  ),	  ΔA76-­‐tRNALeuUAA	  (	  	  ),	  as	  well	  as	  in	  the	  absence	  of	  
tRNA(	  	  )	  and	  in	  the	  absence	  of	  both	  tRNA	  and	  amino	  acid	  (aa)(	  	  ).	  Error	  bars	  represent	  
triplicated	  reactions	  for	  all	  time	  points.	  Absence	  of	  error	  bars	  indicates	  the	  difference	  
between	  the	  triplicates	  was	  small.	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hydrolysis	  and	  AMP	  formation	  was	  observed	  with	  isoleucine	  only	  in	  the	  presence	  of	  
full	   length	   tRNA.	   Interestingly,	   in	   the	   presence	   of	   norvaline	   an	   increase	   in	   ATP	  
hydrolysis	   and	   AMP	   formation	  was	   observed	   in	   the	   presence	   of	   not	   only	   the	   full	  
length	   tRNA	   but	   also	   the	   ΔA76tRNA	   and	   no	   tRNA	   when	   compared	   with	   the	   no	  
tRNA/no	   amino	   acid	   control	   (Fig.	   4.2	   C).	   It	   is	  worth	   noting	   that	   the	   level	   of	   AMP	  
formation	  for	  both	  ΔA76tRNA	  and	  no	  tRNA	  conditions	  were	  similar	  and	  lower	  than	  
the	  full	  length	  tRNA.	  This	  indicates	  that	  the	  norvalyl-­‐adenylate	  formed	  is	  capable	  of	  
being	   hydrolyzed	   at	   the	   synthetic	   site.	   The	   fact	   that	   we	   see	   an	   increase	   in	   ATP	  
hydrolysis	   activity	   in	   the	   presence	   of	   ΔA76tRNA	   and	   no	   tRNA	   indicate	   a	   tRNA	  
independent	  pre-­‐transfer	  editing	  of	  norvaline	  in	  the	  LeuRSΔCP1	  enzyme.	  
Further	  we	  used	  the	  ΔA76tRNA	  to	  test	  the	  pre-­‐transfer	  editing	  activity	  of	  the	  
LeuRS	  wild	   type	   enzyme	   in	   the	   presence	   of	   leucine,	   isoleucine	   and	   norvaline.	   An	  
increase	  in	  ATP	  hydrolysis	  and	  AMP	  formation	  with	  leucine	  or	  isoleucine	  was	  again	  
observed	   only	   in	   the	   presence	   of	   full	   length	   tRNA.	   The	   no	   tRNA	   and	   no	   tRNA/no	  
amino	  acid	  controls	  showed	  no	  ATPase	  activity.	  The	  ΔA76tRNA	  showed	  only	  a	  slight	  
increase	   when	   compared	  with	   the	   controls	   (Fig.	   4.3	   A	   and	   B).	   This	   indicated	   the	  
absence	   of	   adenylate	   hydrolysis	   at	   the	   synthetic	   site	   of	   the	   wild	   type	   enzyme.	  
However,	   in	   the	   presence	   of	   norvaline	   an	   increase	   in	   ATP	   hydrolysis	   and	   AMP	  
formation	  was	   observed	   for	   both	   full	   length	   and	   ΔA76tRNA.	   The	   no	   tRNA	   and	   no	  
tRNA/no	  amino	  acid	  controls	  showed	  no	  activity	  (Fig.	  4.3	  C).	  This	  provides	  evidence	  
for	  the	  hydrolysis	  of	  the	  norvalyl-­‐adenylate	  by	  the	  wild	  type	  LeuRS	  that	  is	  occurring	  
in	  a	  tRNA	  dependent	  manner	  since	  no	  ATPase	  activity	  is	  observed	  in	  the	  absence	  of	  
tRNA.	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Fig.	   4.4.	   Full-­‐length	   LeuRS	   selectively	   hydrolyzes	   misactivated	   norvaline	   via	  
tRNALeuUAA	   dependent	   pre-­‐transfer	   editing.	   Reaction	   mixtures	   contained	   5	   μM	  
tRNALeuUAA	  	  analogues	  and	  1	  μM	  LeuRS.	  Consumption	  of	  ATP	  and	  AMP	  production	  are	  
shown	  on	  the	  left	  and	  right,	  respectively	  in	  the	  presence	  of	  leucine	  (A),	  isoleucine	  (B)	  
and	  norvaline	  (C).	  	  Experiments	  included	  tRNALeuUAA	  (	  	  ),	  ΔA76-­‐tRNALeuUAA	  (	  	  ),	  as	  well	  
as	  in	  the	  absence	  of	  tRNA(	  	  )	  and	  in	  the	  absence	  of	  both	  tRNA	  and	  amino	  acid	  (aa)(	  	  ).	  
Error	  bars	  represent	   triplicated	  reactions	   for	  all	   time	  points.	  Absence	  of	  error	  bars	  
indicates	  the	  difference	  between	  the	  triplicates	  was	  small.	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The	   no	   tRNA	   and	   no	   tRNA/no	   amino	   acid	   control	   for	   ATP	   hydrolysis	   and	  
AMP	  formation	  was	  a	  lot	  tighter	  in	  the	  wild	  type	  enzyme	  when	  compared	  with	  the	  
LeuRSΔCP1	  mutant.	  This	  difference	  can	  be	  attributed	  to	  a	  consistent	  ADP	  formation	  
that	  was	  observed	   for	   the	  LeuRSΔCP1	  mutant	   irrespective	  of	   the	  amino	  acid	  used	  
(data	  not	  shown).	  The	  reason	  for	  this	  ADP	  formation	  is	  not	  clear.	  It	  appears	  that	  the	  




	   The	  different	   tRNA	  analogues	  were	   tested	  against	  wild	   type	   (wt)	  and	  ΔCP1	  
LeuRS	  in	  the	  presence	  of	  cognate	  amino	  acid,	  Leucine	  as	  well	  as	  non-­‐cognate	  amino	  
acids,	   including	  isoleucine	  and	  norvaline	  that	  threaten	  fidelity	  of	  editing	  by	  LeuRS.	  	  
Norvalyl-­‐adenylate	   is	   hydrolyzed	   much	   faster	   when	   compared	   to	   the	   leucyl-­‐	   or	  
isoleucyl-­‐adenylate	   in	   wild	   type	   as	   well	   as	   ΔCP1	   leuRS.	   This	   indicates	   editing	   of	  
norvaline	  at	  the	  synthetic	  active	  site	  of	  LeuRS.	  In	  recent	  times	  there	  has	  been	  debate	  
regarding	   the	   target	   of	   leuRS	   editing	   and	   also	   its	   editing	   mechanism.	   Reports	  
suggest	   that	  E.	  coli	  leuRS	  primarily	  edits	  norvaline	  and	  this	  editing	  occurs	  through	  
CP1	  domain(Cvetesic	  et	  al.	  2014;	  Cvetesic	  et	  al.	  2012).	  Our	  studies	  further	  shed	  light	  
on	  the	  role	  of	  hydrolytic	  editing	  activity	  at	  the	  synthetic	  active	  site	  of	  LeuRS.	  Further	  
we	  also	  show	  that	  this	  editing	  activity	  in	  wild	  type	  LeuRS	  is	  tRNA	  dependent	  where	  
as	  the	  same	  occurs	  in	  a	  tRNA	  independent	  fashion	  in	  ΔCP1	  LeuRS.	  We	  hypothesize	  
that	  the	  interaction	  between	  CP1	  domain	  and	  the	  tRNA	  acceptor	  stem	  are	  important	  
for	  editing	  activity	  at	  the	  synthetic	  site.	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Chapter	  5:	  Biallelic	  Mutations	  in	  VARS	  Encoding	  Cytoplasmic	  ValRS	  




Microcephaly	   is	   a	   neurodevelopmental	   disorder	   that	   is	   characterized	   by	   a	  
reduction	   in	   brain	   size	   accompanied	   by	   varying	   degrees	   of	   intellectual	   disability,	  
seizures	  and	  abnormal	  facial	  features.	  Whole	  exome	  sequencing	  of	  a	  patient	  sample	  
done	   by	   Prof.	   May	   Malicdan’s	   group	   at	   NHGRI	   identified	   novel	   compound	  
heterozygous	   variants	   in	   VARS	   encoding	   valyl	   tRNA	   synthetase	   (ValRS).	   ValRS	   is	  
essential	  for	  protein	  synthesis	  and	  cellular	  function,	  mutation	  in	  this	  enzyme	  leads	  
to	  diseases.	  
ValRS	   is	  part	  of	   to	   the	  class	   Ia	  aminoacyl	   tRNA	  synthetase.	   It	   is	   responsible	  
for	  the	  attachment	  of	  the	  branched	  chain	  amino	  acid,	  valine	  to	  tRNAVal.	  	  The	  identity	  
elements	  that	  facilitate	  this	  recognition	  are	  A35	  and	  C36	  bases	  of	  the	  anticodon	  and	  
the	  phylogenetically	  conserved	  discriminator	  base	  A73	  of	  tRNAVal.	  Substitution	  at	  any	  
of	  these	  nucleotides	  causes	  a	  decrease	  in	  aminoacylation	  activity.	  	  
The	  anticodon	  loop	  of	  tRNAVal	  is	  disordered.	  Nucleotide	  at	  position	  34	  points	  
outwards	   into	   the	   solution.	   While	   nucleotides	   A35	   and	   C36	   form	   base	   stacking	  
interactions	  with	  a	  conserved	  Phe	  residue	   from	  the	  helix	  bundle	  domain	  of	  ValRS.	  
The	  first	  and	  third	  helix	  of	  the	  helix	  bundle	  domain	  of	  ValRS	  contact	  the	  tRNAVal	  and	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help	  clamp	  it	  in	  position.	  Aminoacylation	  assay	  were	  done	  to	  determine	  the	  activity	  
of	  the	  mutant	  ValRS	  identified	  in	  the	  patient.	  
	  
5.2.	  Methods	  	  
Bovine	  liver	  crude	  tRNA	  (Sigma)	  was	  re-­‐suspended	  in	  1	  mL	  of	  10	  mM	  HEPES	  
pH	   7.5,	   0.1	   mM	   EDTA.	   Since	   mammalian	   tRNA	   often	   lacks	   CCA	   at	   the	   3’-­‐end,	   a	  
previously	  published	  method	  was	  employed	   to	  process	   the	   tRNA	  using	  E.coli	  CCA-­‐
adding	   enzyme,	  with	   the	   exception	   of	   utilizing	   a	   temperature	   of	   37	   °C	   (Pang	   and	  
Martinis	  2009).	  The	  full-­‐length	  tRNA	  was	  phenol-­‐extracted	  using	  2	  mL	  Phase	  Lock	  
Gel	   tubes	   (Eppendorf)	  and	  subsequently	  ethanol-­‐precipitated	  overnight.	  The	   tRNA	  
was	   re-­‐suspended	   in	   10	   mM	   HEPES	   buffer	   pH	   7.5,	   0.1	   mM	   EDTA	   for	   use	   in	  
aminoacylation	  reaction.	  
Aminoacylation	  was	  carried	  out	  in	  the	  presence	  of	  50	  mM	  HEPES,	  pH	  7.4,	  15	  
mM	  MgCl2,	   20	  mM	  KCl,	   1	  mM	  dithiotheritol,	   50	  μM	  L-­‐[14C]-­‐valine	   (0.27	  Ci/mmol),	  
1.5	   mg/mL	   of	   full	   length	   bovine	   liver	   tRNA	   and	   mouse	   embryonic	   cell	   lysate	  
containing	  320	  μg/mL	  of	  protein	  or	  human	  fibroblast	  cell	  lysate	  at	  920	  μg/mL.	  The	  
human	   fibroblast	   lysate	   had	   reduced	   expression	   of	   ValRS	   when	   compared	   to	   the	  
mouse	  embryonic	   stem	  cell	   lysates.	  Therefore,	   for	   the	  purpose	  of	   carrying	  out	   the	  
aminoacylation	   assay	   the	   lysate	   from	  human	   fibroblast	   cells	  was	   used	   at	   a	   higher	  
protein	   concentration.	   Aliquots	   (5	   μL)	   were	   taken	   at	   different	   time	   points	   and	  
quenched	   on	  Whatman	   filter	   pads	   that	  were	   pre-­‐soaked	  with	   10%	   trichloroacetic	  
acid	  (TCA).	  The	  pads	  were	  washed	  three	  times	  for	  8	  min	  each	  with	  ice-­‐cold	  5%	  TCA	  
and	  then	  treated	  with	  ice-­‐cold	  95%	  ethanol	  for	  8	  min.	  The	  washed	  pads	  were	  then	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dried	   under	   a	   heat	   lamp.	   Radioactivity	   was	   quantified	   in	   a	   Beckman	   LS	   6500	  
scintillation	  counter	  (Beckman	  Coulter,	  Fullerton,	  CA).	  
	  
5.3.	  Results	  
ValRS	   from	   the	   patient	   has	   a	  mutation	   in	  Met1064	   residue	   that	   is	   present	  
near	  the	  turn	  of	  the	  second	  helix	  of	  the	  helix	  bundle	  domain	  (Fig.	  5.1).	  Though	  this	  
residue	  is	  not	  in	  direct	  is	  contact	  with	  the	  tRNA,	  it	  is	  part	  of	  highly	  conserved	  region	  
of	   ValRS.	   It	   is	   possible	   this	   mutation	   to	   isoleucine	   may	   result	   in	   conformational	  
changes	   in	   the	   helix	   bundle	   domain	   that	   is	   essential	   for	   tRNAVal	   binding	   and	  
recognition.	  	  
	  
Fig.	  5.1.	  The	  model	  of	  human	  ValRS	  with	  tRNA	  bound.	  The	  possible	  impact	  of	  the	  
M1064I	  mutation	   on	   ValRS-­‐tRNA	   binding	   is	   illustrated	   by	   showing	   side	   chains	   as	  
space	  filling	  for	  Met	  1064	  and	  Cys	  950,	  as	  well	  as	  for	  conserved	  residues	  at	  or	  near	  
the	   interface:	  Arg	  947,	  Phe	  949,	  Asn	  951,	  Lys	  952,	  Asn	  955,	  Ala	  956,	  and	  Phe	  959.	  
The	  M1064I	  mutation	  might	   also	  perturb	   the	   interface	  between	   the	   catalytic	   core	  
domain	  (colored	  salmon)	  and	  the	  anticodon-­‐binding	  domain	  (green)	  (Stephen	  et	  al.	  
2018).	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   Aminoacylation	   activity	   was	   measured	   in	   the	   lysate	   obtained	   from	   the	  
patient	   fibroblast	   cells	   against	   total	   tRNA	   from	   bovine	   liver	   cells.	   Initial	   assay	  
showed	   no	   significant	   aminoacylation	   activity	   for	   lysate	   from	   either	   patient	   or	  
control	  fibroblast	  cells.	  A	  previously	  published	  method	  employed	  activation	  of	  total	  
tRNA	  with	  CCA-­‐adding	  enzyme	  prior	  to	  use	  in	  aminoacylation.	  Once	  the	  total	  tRNA	  
was	   activated	  using	  CCA-­‐adding	   enzyme.	  Aminoacylation	   activity	  was	   observed	   in	  
the	   lysate	   from	  the	  control	   fibroblast	  cells.	  This	  was	  probable	  because	  only	  a	  very	  
small	   fraction	  of	  the	  total	  tRNA	  had	  an	  intact	  3’ CCA-­‐terminus,	  which	  is	  crucial	   for	  
aminoacylation	  activity	  of	  the	  tRNA.	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   Aminoacylation	  assay	  determined	  that	  lysate	  from	  the	  patient	  fibroblast	  cells	  
showed	   an	   approximately	   4	   times	   decreased	   activity	   for	   aminoacylation	   when	  
compared	  to	  a	  control	  (Fig.	  5.2).	  Therefore,	   the	  mutations	  identified	  in	  ValRS	  from	  
patient	   impair	   the	   ability	   of	   this	   enzyme	   to	   aminoacylate	   tRNAVal	  with	   valine.	   A	  
similar	  decrease	   in	  aminoacylation	  activity	  was	  observed	  when	  lysate	   from	  mouse	  
embryonic	   stem	   cells	   that	   contained	   a	  ValRS	  double	   knockout	  was	   assayed	   in	   the	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5.4.	  Discussion	  
	   The	   missense	   mutation	   occurs	   in	   a	   highly	   conserved	   region	   of	   the	   tRNA	  
binding	  domain.	  The	  decrease	  in	  aminoacylation	  activity	  for	  the	  patient	  ValRS	  when	  
compared	  to	  control	  indicates	  that	  potentially	  both	  steps	  of	  enzymatic	  reaction	  are	  
being	   affected.	   Additionally,	   VARS	   mutations	   produce	   severe	   neurological	  
implications,	   illustrating	   the	   essential	   nature	   of	   this	   gene	   in	   the	   development	   and	  
proper	  functioning	  of	  the	  nervous	  system.	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Chapter	  6:	  Functional	  Significance	  of	  Intra-­‐Organism	  Variation	  in	  




	   In	   addition	   to	   donating	   amino	   acids	   to	   protein	   synthesis,	   aminoacyl-­‐tRNA	  
participates	   in	   the	   modification	   of	   peptidoglycan	   precursors	   and	   lipids,	   tagging	  
proteins	   for	   recycling,	   and	   antibiotic	   synthesis.	   While	   it	   is	   well	   established	   that	  
structural	  features	  can	  be	  integral	  to	  tRNA	  performance	  throughout	  the	  translation	  
pathway,	   there	   are	   only	   a	   few	   instances	   where	   distinctive	   structures	   are	   known	  
prerequisites	   for	   tRNA	  entry	   into	  a	  non-­‐canonical	  biosynthetic	  pathway.	   Indeed,	   it	  
remains	  unclear	  whether	  these	  cases	  are	  the	  exception	  or	  the	  rule.	  	  	  
Based	  on	  bioinformatics	  analysis	  of	  1578	  fully	  sequenced	  bacterial	  genomes	  
from	   tRNA	   DB-­‐CE	   database,	   Dr.	   Margaret	   E.	   Saks	   has	   identified	   unusual	   tRNA	  
structures	  (Table	  6.1).	  These	  unusual	  tRNALeu	  structures	  (Fig.	  6.1)	  partition	  within	  
sets	   of	   isoacceptors	   from	   single	   species,	   including	   the	   pathogen	   M.	   tuberculosis	  
(Mtb)	   (unpublished	   results).	   However,	   X-­‐ray	   crystal	   structures	   of	   E.	   coli	   LeuRS	  
support	  protein-­‐RNA	  interactions	  between	  the	  C-­‐terminal	  domain	  and	  variable	  loop	  
that	  could	  be	  important	  to	  aminoacylation	  (Fig.	  6.2).	  
	   	  
	   	  59	  
	  
	  
Until	   now,	   it	   seemed	   that	   bacteria	   only	   encode	   a	   Type	   II	   (long	   stem-­‐loop)	  
structural	  form	  of	  leucine,	  serine,	  and	  tyrosine	  tRNAs.	  	  Yet	  because	  tRNATyr	  is	  Type	  I	  
(short	  variable	  loop)	  in	  the	  archaea	  and	  eukarya,	  it	  is	  clear	  that	  Type	  switching	  has	  
occurred	  over	  the	  course	  of	  evolution.	  Here	  we	  report	  the	  unexpected	  phenomenon	  
of	   intra-­‐organism	   type-­‐variation	   in	   which	   the	   chromosomes	   of	   some	   medically	  
important	   organisms	   encode	   both	   Type	   I	   and	   Type	   II	   leucine	   tRNAs.	   This	   is	  
particularly	   surprising	   given	   that	   these	   organisms	   encode	   a	   single	   form	   of	   the	  
cognate	  synthetase.	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Fig.	  6.	  1.	  Comparison	  between	  tRNALeu	  from	  Mtb	  and	  E.	  coli.	  The	  Mtb	  tRNALeu	  
isoacceptors	  CAA	  and	  UAA	  are	  type	  I	  while	  all	  three	  E.coli	  tRNALeu	  isoacceptors	  and	  
Mtb	  tRNALeu	  isoacceptor	  CAG	  are	  type	  II.	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6.2.	  Methods	  
	   The	  materials	  and	  methods	  used	  are	  similar	  to	  that	  described	  in	  chapter	  II.	  
	  
6.3.	  Results	  
	   The	  E.	  coli	  LeuRS	  and	  its	   interaction	  with	  its	  cognate	  tRNALeu	  was	  chosen	  as	  
the	   control	   on	   account	   of	   the	   wealth	   of	   information	   available	   on	   this	   system	  
(Boniecki	  and	  Martinis	  2012;	  Boniecki	  et	  al.	  2008;	  Englisch	  et	  al.	  1986;	  Karkhanis	  et	  
al.	  2007a;	  Larkin	  et	  al.	  2002).	  Initial	  experiments	  were	  carried	  out	  to	  determine	  the	  
cross-­‐reactivity	   between	   the	  E.	   coli	   tRNA	   isoacceptors	   and	   purified	  Mtb	   LeuRS.	   It	  
was	  observed	  that	  while	  Mtb	  LeuRS	  showed	  high	  reactivity	  for	  its	  cognate	  tRNA,	  its	  
Fig.	  6.2.	  Interaction	  between	  LeuRS	  and	  tRNALeu	  in	  E.	  coli.	  The	  C-­‐terminal	  domain	  
of	  LeuRS	  (orange	  ribbon)	  contacts	  the	  variable	  arm	  of	  tRNALeu	  (grey	  surface).	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reactivity	  towards	  the	  E.	  coli	  tRNA	  was	  low	  (Fig.	  6.3).	  The	  CAG	  isoacceptor,	  Type	  II	  
for	  both	  E.	  coli	  and	  Mtb,	  was	  used	   to	  during	   this	  experiment	   to	  ensure	   the	   results	  
showed	   no	   bias	   on	   account	   of	   tRNA	   type.	   For	   further	   experiments	   the	  
aminoacylation	   of	  E.	   coli	   LeuRS	  with	   its	   cognate	   tRNAs	  were	   compared	   to	   that	   of	  
Mtb	  LeuRS	  with	  its	  cognate	  tRNA.	  
	  
	  
	   Optimization	   experiments	   were	   performed	   to	   determine	   conditions	   that	  
could	   be	   used	   consistently	   between	   E.	   coli	   and	   Mtb.	   Presence	   of	   salt	   at	  
concentrations	  ranging	  from	  10	  to	  150	  mM	  is	  commonly	  observed	  in	  protocols	  for	  E.	  

























Fig.	  6.3.	  Mtb	   LeuRS	   shows	   lower	  activity	   towards	  E.	  coli	   tRNA.	  Reactions	  were	  
carried	  out	  using	  4	  µM	  tRNALeuCAG	  and	  5	  nM	  Mtb	  LeuRS	  at	  37°C.	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out	   aminoacylation	   assay	   with	   Mtb	   LeuRS	   it	   was	   observed	   that	   presence	   of	   high	  
concentration	  of	   salt	  was	  detrimental	   to	   the	   rate	   of	   aminoacylation.	  However,	   the	  
leucylation	   activity	   of	   E.	   coli	   remains	   constant	   over	   a	   range	   of	   salt	   concentration	  
(Fig.	  6.4).	  
	  
Fig.	   6.4.	   Mtb	   LeuRS	   Aminoacylation	   is	   inactivated	   at	   high	   salt	   concentration.	  
Reactions	  were	  carried	  out	  using	  4	  µM	  Mtb	  tRNA	  and	  5	  nM	  Mtb	  LeuRS	  (A)	  and	  using	  1	  
µM	  E.	  coli	  tRNA	  and	  5	  nM	  E.	  coli	  LeuRS	  at	  37°C.	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  Mtb	  tRNALeu	  isoaceptors	  




















	  Eco	  tRNALeu	  isoaceptors	  
Eco	  tRNALeu	  against	  Eco	  LeuRS	  
Fig.	  6.5.	  Aminoacylation	  rates	  partition	  between	  the	  Type	  I	  and	  Type	  II	  tRNALeu.	  
Reaction	  were	   carried	   out	   at	   37°C	   using	   1	   μM	   in-­‐vitro	   transcribed	   tRNA	   and	   1	   nM	  
cognate	  LeuRS.	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Comparison	  of	  aminoacylation	  activity	  between	  E.	  coli	  and	  Mtb	  LeuRSs	  with	  
their	  respective	  tRNA	  isoacceptors	  shows	  that	  the	  rate	  of	  aminoacylation	  in	  E.	  coli	  is	  
greater	  than	  Mtb	  (Fig.	  	  6.5).	  This	  difference	  can	  easily	  be	  attributed	  to	  the	  difference	  
in	   growth	   rate	   between	   the	   two	   organisms.	  While	   the	   doubling	   time	   for	  E.	   coli	   is	  
merely	  20	  minutes	  (Sezonov	  et	  al.	  2007)	   that	   for	  Mtb	   is	  a	  minimum	  of	  14.7	  hours	  
(James	   et	   al.	   2001).	   Evaluating	   aminoacylation	   rate	   for	   isoacceptors	   within	   each	  
organism,	   it	   can	   be	   seen	   that	   difference	   between	   E.	   coli	   isoacceptors	   is	   smaller	  
compared	   to	  Mtb.	   The	   type	   II	   CAG	   isoacceptor	   in	  Mtb	   has	   an	   aminoacylation	   rate	  
that	   is	   5	   times	   higher	   than	   the	   type	   I	   UAA	   and	   CAA	   isoacceptors.	   Though	   this	  
number	   does	   not	   seem	   to	   be	   that	   significant	   at	   first,	   it	   may	   however	   result	   in	  
differences	  in	  vivo	  particularly	  for	  a	  slow	  growing	  organism	  such	  as	  Mtb.	  	  
6.4.	  Discussion	  
There	   is	   a	   need	   for	   further	   evaluation	   into	   the	   role	   that	   this	   structural	  
variation	   plays	   in	   protein	   synthesis	   and	   other	   tRNA-­‐dependent	   biochemical	  
transformations.	  Though	  the	  difference	  in	  rates	  of	  leucylation	  between	  the	  different	  
tRNA	   types	   appears	   to	   be	   small,	   it	   could	   be	   potentially	   significant	   in	   vivo.	  
Additionally,	   editing	   activities	  of	   the	   tRNA	   types	  need	   to	  be	   compared	   in	  order	   to	  
gain	  more	  complete	  understanding	  of	  the	  effect	  on	  protein	  synthesis.	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Chapter	  7:	  	  Conclusions	  
	  
	  
The	  AARS	  family	  of	  enzyme	  is	  critical	  to	  protein	  synthesis	  and	  several	  other	  
functions	  in	  the	  cell.	  A	  number	  of	  these	  functions	  are	  linked	  to	  the	  enzyme’s	  ability	  
of	   precisely	   identifying	   an	   amino	   acid,	   its	   cognate	   tRNA	   and	   forming	   the	  
aminoacylated	   tRNA.	   The	   AARS	   catalytic	   core	   and	   in	   certain	   cases	   the	   editing	  
domain	  are	  central	  to	  this	  function	  and	  have	  been	  studied	  extensively.	  	  
The	  instability	  of	  the	  aminoacyl	  adenylate	  produced	  at	  the	  AARS	  active	  site	  is	  
a	   major	   factor	   contributing	   to	   the	   difficulty	   in	   carrying	   out	   mechanistic	  
investigations.	  A	  useful	  tool	  to	  circumvent	  this	  problem	  is	  use	  of	  tRNA	  analogues.	  A	  
number	  of	  useful	  methods	  are	  available	  for	  preparation	  of	  tRNA	  analogues	  (Minajigi	  
and	  Francklyn	  2008;	  Nordin	  and	  Schimmel	  2002;	  Sprinzl	  and	  Cramer	  1975a;	  Zhao	  
et	  al.	  2015).	  	  
Given	  the	  idiosyncratic	  nature	  of	  tRNA	  a	  comparison	  between	  the	  routes	  for	  
tRNA	   analogue	   synthesis	   is	   a	   useful	   resource.	   	   Our	   analysis	   reveals	   that	   the	   best	  
method	   for	   synthesis	   when	   working	   with	   in	   vito	   transcribed	   tRNA	   is	   a	   one-­‐step	  
reaction	  of	  ATP	  analogue	  addition	  to	  a	  designer	  ΔA76tRNA.	  The	  greatest	  advantage	  
of	   this	   method	   is	   a	   complete	   control	   on	   the	   homogeneity	   of	   the	   synthesized	  
analogue.	  Previous	  studies	  as	  well	  as	  our	  results	   indicate	   that	   the	  efficiency	  of	   the	  
CCA-­‐adding	  enzyme	  is	  nucleotide	  dependent	  (Cho	  et	  al.	  2003).	  Therefore,	  exchange	  
reactions	  may	  suffer	  from	  the	  problem	  posed	  by	  the	  nature	  of	  analogue	  that	  is	  being	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utilized.	   Additionally,	   the	   availability	   of	   the	   large	   number	   of	   restriction	   digestion	  
enzymes	  will	  allow	  for	  the	  design	  and	  use	  of	  a	  wide	  variety	  of	  tRNA	  substrates.	  	  
The	   editing	   mechanism	   of	   E.	   coli	   LeuRS	   has	   been	   controversial	   and	   most	  
reports	   suggest	   a	  post-­‐transfer	  editing	  mechanism	   for	   this	   enzyme	   (Cvetesic	   et	   al.	  
2014;	   Cvetesic	   et	   al.	   2012;	   Englisch	   et	   al.	   1986).	  While	   there	   are	   assays	   that	   can	  
determine	  pre-­‐transfer	  editing	  uncoupling	  post-­‐transfer	  editing	  from	  total	  editing	  is	  
challenging	   (Splan	   et	   al.	   2008).	   Previous	   investigations	   involving	   a	  mutant	   LeuRS	  
enzyme	  from	  E.	  coli	  that	  was	  missing	  the	  CP1	  hydrolytic	  domain	  unveiled	  the	  latent	  
editing	  activity	  of	  the	  LeuRS	  catalytic	  core	  (Boniecki	  et	  al.	  2008).	  	  
Combining	   tRNA	   analogues	   with	   E.	   coli	   LeuRS-­‐ΔCP1	   provides	   a	   unique	  
system	  that	  allows	  us	  to	  study	  the	  LeuRS	  editing	  activity	  in	  the	  absence	  of	  any	  bias	  
on	   account	   of	   CP1	   editing	   or	   post-­‐transfer	   editing.	   Interestingly,	   it	   was	   observed	  
while	  norvalyl-­‐tRNALeu	  is	  edited	  in	  a	  post-­‐transfer	  manner,	  the	  catalytic	  core	  is	  also	  
capable	  of	  editing	  norvalyl-­‐adenylate.	  	  
The	   importance	  of	   the	   interaction	  between	   the	   tRNA	  CCA-­‐end	   and	   the	  CP1	  
domain	   (Palencia	   et	   al.	   2012)	   is	   also	   highlighted	   when	   comparing	   the	   editing	  
activity	   between	   the	   LeuRS-­‐ΔCP1	   and	   the	   wild-­‐type	   enzyme.	   The	   ΔA76tRNA	  
analogues	  designed	  here	  can	  be	  further	  used	  in	  conjunction	  with	  other	  post-­‐transfer	  
editing	  deficient	  LeuRS	  mutants,	  such	  as	  the	  LeuRS	  T252Y	  (Mursinna	  and	  Martinis	  
2002).	  Here,	   replacement	   of	   threonine	  with	   the	   bulky	   tyrosine	   residue	   blocks	   the	  
entry	   of	   aminoacyl-­‐tRNA	   into	   the	  hydrolytic	   active	   site.	   It	  would	  be	   interesting	   to	  
investigate	   this	   mutant	   in	   the	   presence	   of	   an	   unchargeable	   tRNA	   to	   better	  
understand	  pre-­‐transfer	  editing	  by	  LeuRS.	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  The	  interaction	  between	  tRNA	  and	  LeuRS	  and	  its	  effect	  on	  aminoacylation	  is	  
further	  highlighted	  in	  Mtb.	  Surprisingly,	  in	  Mtb	  tRNA	  isoacceptors	  UAA	  and	  CAA	  are	  
present	  as	  type	  I	  instead	  of	  the	  usual	  type	  II.	  The	  results	  indicate	  that	  the	  type	  I	  Mtb	  
tRNAs	   appear	   to	   be	   slightly	   less	   reactive	   than	   its	   type	   II	   counterpart.	   These	  
experiments	  focused	  on	  analyzing	  the	  leucylation	  activity.	  	  
The	   editing	   mechanism	   adopted	   LeuRS	   is	   amino	   acid	   dependent.	   E.	   coli	  
LeuRS	   wild-­‐type	   primarily	   edits	   via	   the	   post	   transfer	   mechanism.	   However,	   our	  
results	   have	   indicated	   that	   the	   catalytic	   core	   has	   some	   hydrolytic	   activity	   with	  
respect	   to	  norvalyl-­‐adenylate.	   It	  would	  be	   interesting	   to	  note	   if	  Mtb	  LeuRS	   shows	  
any	  dependence	  on	  amino	  acid	  and	  the	  effect	  of	  tRNA	  type	  on	  such	  dependence.	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